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Niemann-Pick disease, type C (NPC) is a rare (1:120,000-150,000) autosomal recessive 
lysosomal lipidosis resulting in a progressive and fatal neurological deterioration.  There 
is much about the pathogenesis and natural history of this complex, heterogeneous 
disorder that remains unknown.  Limited literature suggests auditory dysfunction is part 
of the phenotype, but an aspect of the disease process that is poorly understood and, 
indeed, has likely been underreported.  Experiment one includes auditory data from 55 
patients with NPC seen at the National Institutes of Health between 8/14/2006 and 
12/27/2010.  These data confirm a prevalent high frequency hearing loss that 
progressively worsens in at least some individuals.  Retrocochlear involvement is 
common, with abnormalities that suggest a profile of auditory neuropathy spectrum 
disorder in some patients. Analysis of late-onset cases suggests hearing loss is a 
premonitory symptom in this disease subcategory.   
The investigation was expanded to include the mouse model for NPC 
(BALB/cNctr-Npc1m1N/J), in which symptomatology is clinically, biochemically, and 
morphologically comparable with affected humans.  There have been no previous reports 
of auditory function in NPC mice, although brainstem histopathology has been localized 
to the auditory pathway.  Experiment two includes auditory brainstem response (ABR) 
and otoacoustic emission (OAE) data revealing a high frequency hearing loss in mutant 
NPC mice as early as postnatal day (p) 20, which becomes progressively poorer across 
the experimental lifespan.  With support for both a cochlear and retrocochlear site of 
lesion, OAE level and ABR latency data provide surprising evidence for a disruption in 
maturational development of the auditory system in diseased animals, which may add a 
unique perspective on the role of NPC pathogenesis.  This comparative, translational 
study has, for the first time, addressed comprehensively the existence of, and implications 
for, auditory dysfunction in NPC.  Similar auditory phenotypes between affected humans 
and mutant mice should aid future efforts in refining site of lesion.  In combination, these 
data support the auditory system as a useful marker for disease status and provide 
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CHAPTER 1: INTRODUCITON 
 
Niemann-Pick, type C disease (NPC) is a rare (1:120,000-150,000), genetic 
lysosomal lipidosis with a hallmark neurological deterioration that is fatal in all cases.  It 
is part of a family of metabolic storage disorders resulting in a pathological accumulation 
of lipids in numerous organs and systems throughout the body.  The primary metabolic 
defect in NPC is abnormal cholesterol trafficking from lysosomes (Liscum & Faust, 
1987; Liscum, Ruggiero, & Faust, 1989), and the characteristic phenotype includes 
hepatic dysfunction and neurological decline.  Currently, there is no effective treatment 
or cure. 
 Despite major developments over the last century in elucidating the metabolic and 
genetic bases of NPC, there is much about this disease that remains a mystery.  This is, in 
part, due to the inherent difficulty associated with studying such a complex and 
heterogeneous disorder.  Among the challenges for researchers and clinicians 
investigating NPC are the highly variable ages of onset and diagnosis, and the broad, 
multifaceted clinical spectrum associated with the disease. 
 It is now known that NPC is the result of biallelic mutations in either NPC1 or 
NPC2 (Carstea, Morris, Coleman, Loftus, Zhang, Cummings, et al., 1997; Naureckiene et 
al., 2000) and, while 95% of all affected individuals have mutations in NPC1, there 
appears to be no significant difference in how the disease manifests between mutations in 
either of these genes (e.g., Ikonen, & Hölttä-Vuori, 2004).  The ensuing biochemical 
defect is an over-accumulation of exogenous and unesterified cholesterol within cells and 
tissues throughout the body, including areas with high concentrations of lipids within the 




The early symptoms of NPC commonly involve the hepatic system; however, diagnosis 
is typically delayed until the onset of neurological manifestations, which may include, 
among other complications, cerebellar ataxia, dysarthria, dysphagia, dystonia/hypotonia, 
cataplexy, and seizures.  In some cases, neurological involvement may progress to states 
of psychosis and dementia.   
 Preliminary evidence from limited literature on the subject suggests the auditory 
system is affected during the course of this disease (e.g., Pikus, 1989), although the full 
natural history of the auditory phenotype is unknown.  Indeed, auditory manifestations 
have likely been underreported given the difficulty in obtaining behavioral audiological 
evaluations in a neurologically compromised population and the inability of many 
affected individuals to self-report hearing difficulties. 
 The handful of case studies and articles in the literature describing hearing in 
NPC includes sporadic descriptions of high-frequency peripheral hearing loss, acoustic 
reflex abnormalities, and auditory brainstem response (ABR) dysfunction, although none 
are depicted with any great detail.  As a result, there remains a clear need to examine 
comprehensively the auditory phenotype in NPC characterizing both how the dysfunction 
manifests and if, like the global neurological phenotype, it is progressive. 
In recent years, the discovery of several animal models for NPC has significantly 
advanced understanding of the disease and the ability to examine its effect on various 
biological systems.  Research with animal models offers many advantages over those 
challenges posed by studying a genetically heterogeneous species, such as humans, where 
quantifying the contribution of a specific genetic mutation is difficult.  The mouse model 




morphologically comparable with affected humans (Kolodny, 2000), has emerged as an 
invaluable species for studying this disorder.  However, unlike humans with NPC, there 
are no reports documenting auditory function in the NPC mouse.  Luan et al. (2008) 
identified histological brainstem pathology localized to the auditory pathway in NPC 
mice, which is the best evidence to date suggesting the auditory system may be 
compromised in this model.  Further exploration is required to confirm an auditory 
phenotype in the mouse model for NPC and establish the extent to which it is comparable 
to findings in humans. 
The principal goal of the present study was to evaluate comprehensively the 
auditory phenotype in NPC to understand better the natural history of the disease and its 
effect on the auditory system.  With this aim in mind, auditory function in both affected 
humans and mice was examined.  Studying auditory function in humans with NPC 
provides unique insights into the behavioral manifestations and quality of life issues for 
these individuals, and working with the mouse model allows a focused examination of 
the effects of a specific genetic mutation on the auditory system not possible to obtain in 
other heterogeneous populations.  The synergistic combination of the two projects will 















CHAPTER 2: AUDITORY FUNCTION IN HUMANS WITH NIEMANN-PICK 
DISEASE, TYPE C (NPC) 
Review of the Literature 
Overview 
In 1914 a German pediatrician named Albert Niemann published a case study 
describing a Jewish infant with neurodegeneration and hepatosplenomegaly (Niemann, 
1914).  He noted that the child’s symptoms were similar to those observed in Gaucher 
disease and believed he was seeing a new variant of the known lipid storage disorder.  
More than a decade later, Ludwig Pick isolated the new disease by characterizing its 
unique histopathology, determining it was distinct from Gaucher disease (Pick, 1933), 
and labeled it Niemann-Pick disease (NPD).  Initially, Pick believed this novel 
neurological malady was fatal in all patients by the time they reached the age of two 
years; however, in 1958 Crocker and Farber published a seminal account of 18 patients 
with NPD ranging in age from four months to 19 years.  Crocker (1961) later divided 
these ‘atypical cases’ into four distinct subgroups based on their clinical and biochemical 
phenotypes, and genealogy: type A, B, C, and D. 
Today, NPD is known as a group of autosomal recessive, metabolic lipid storage 
disorders that cause an accumulation of harmful amounts of lipids in various organs and 
tissues throughout the body.  Lipids, or fat molecules, are vital components to all 
biological cells, most critically involved in cellular structure and function.  The 
arrangement and distribution of lipids can vary significantly, especially in membranes 
within the central nervous system (CNS), but also in organs and peripheral tissues (Percy, 




in all subtypes of the disease, is not the result of abnormal molecular structure or 
production.  Instead, NPD is caused by impairments in the mechanisms responsible for 
lipid breakdown, or transportation away from a cell. 
It is now understood that the cluster of diseases that comprise NPD represents two 
primary categories of dysfunction.  The first are those with a deficiency in acid 
sphingomyelinase (ASM).  This enzyme is charged with breaking down the lipid 
sphingomyelin, and is deficient in NPD types A and B.  The second category includes 
those cases with defects in intracellular transportation of cholesterol, observed in types C 
and D (Kolodny, 2000).  Both cholesterol and sphingomyelin are types of lipids housed 
within cell membranes of most, if not all animal tissues.  Although there are only two 
principal categories of metabolic dysfunction, types of NPD can differ significantly in 
their pathophysiology and clinical manifestations. 
All forms of NPD are associated with hepatosplenomegaly (enlargement of the 
liver and spleen).  NPD, type A (NPA) and type B (NPB), both caused by an ASM 
deficiency, differ significantly in disease presentation and progression.  NPA is an acute, 
neurovisceral form (Elleder & Cihula, 1983), with onset during infancy, severe 
neurological manifestations, and rapid progression toward death.  NPA occurs more 
frequently than NPB, with a disproportionately high prevalence in the Ashkenazi Jewish 
population (Weinstein, 2007).  NPB has a juvenile onset, does not involve the nervous 
system, and survival into adulthood is common (Pavlu-Pereira et al., 2005).  Respiratory 
problems secondary to pulmonary infiltration occur frequently in NPA and NPB.   
The NPD variant, labeled type D by Crocker (1961) has only been reported in 




known as Nova Scotia (Winsor & Welch, 1978).  Other than this distinct ancestry, the 
type D variant of NPD is phenotypically indistinguishable from NPD type C (NPC) and 
shares a common molecular aberration.  Consequently, type D is no longer recognized as 
a distinct NPD classification (Vanier & Millat, 2003). 
 NPC, which is the primary focus of this paper, is a complex, heterogeneous 
disorder characterized by hepatosplenomegaly and a neurological deterioration that is 
ultimately fatal.  The incidence of NPC is estimated to be one in every 120,000 to 
150,000 individuals; however, because it is so rare and because it is frequently 
misdiagnosed, this may be an underestimation.  NPC is panethnic (Vanier & Millet, 
2003) and occurs more frequently than NPA and NPB combined (Ikonen, & Hölttä-
Vuori, 2004).   
A major breakthrough in the science of NPD occurred with identification of the 
defective ASM enzyme in NPA and NPB (Brady, Kanfer, Mock, & Fredrickson, 1966).  
This significant advancement, however, paradoxically delayed the discovery of the 
metabolic bases of NPC for years as scientists labored to connect NPC with a 
sphingomyelinase deficiency.  It was not until 1984 that Pentchev and colleagues initially 
linked NPC with cholesterol metabolism.  Following this connection, Liscum published 
two seminal articles (Liscum & Faust, 1987; Liscum et al., 1989) establishing, for the 
first time, that the specific metabolic defect in NPC involves cholesterol trafficking from 
lysosomes (for review see Pentchev, 2004).    
Perhaps the most significant recent development in NPC research came with the 
discovery of the underlying genetic defects.  The NPC1 mutation (18q11) was identified 




flurry of research into the causative molecular pathology of NPC.  As of the year 2000, 
36 NPC1 mutations had been described in the literature (Greer, et al., 1998,1999; Millat, 
et al., 1999; Yamamoto, et al., 1999).  By 2003, the number more than tripled (Vanier & 
Millat, 2003), and today NPC1 is associated with over 240 disease-causing allelic 
mutations (Runz, 2009).  During this period, strong evidence emerged to suggest the 
existence of a second gene linked to NPC.   Vanier, Duthel, Rodriguez-Lafrasse, 
Pentchev, and Carstea (1996) reported a linkage analysis on five families with NPC that 
suggested a second causative locus.  Naureckiene et al. (2000) ultimately identified a 
second mutation in HEI/NPC2, most commonly referred to as the NPC2 mutation 
(14q24.3).  More than 95% of patients with NPC have mutations in NPC1, however there 
appears to be no significant difference in how the disease manifests in those with 
mutations in either NPC1 or NPC2.  While some investigators suggest NPC2 causes more 
severe symptoms and pronounced pulmonary involvement compared to NPC1 (Millat, et 
al., 2001), most reports state that the two complementation groups are clinically and 
biochemically indistinguishable (e.g., Ikonen, & Hölttä-Vuori, 2004). 
Molecular aberrations in NPC1 and NPC2 have complex and multifaceted 
outcomes on cellular function.  The primary biochemical defect is abnormal processing 
of low-density lipoprotein (LDL)-derived cholesterol, which is partly responsible for 
regulating cholesterol synthesis within tissues of the body.  As a result, affected cells are 
unable to transport exogenous cholesterol out, and accumulate a harmful amount of 
unesterified cholesterol (Ikonen, & Hölttä-Vuori, 2004).  Cholesterol accumulation is the 
dominant cellular phenotype, although multiple other lipids can accrue within affected 




2004), both critical molecules in signal transmission through cells and neural tissues.  
There are high concentrations of both cholesterol and sphingolipids within the brain, 
specifically in myelin and neural plasma membranes comprised of fat molecules and 
proteins known as lipid rafts (Vincent et al., 2003).  
While many individuals with NPC are initially diagnosed based on their clinical 
presentation, the definitive diagnosis is made through cytological and biochemical 
assessment.  Most commonly, skin fibroblast samples are stained with the antibiotic 
filipin, which binds to unesterified cholesterol and causes a distinct fluorescent output.  A 
second diagnostic approach is biochemically monitoring fibroblasts to assess the rate of 
LDL-cholesterol esterification (e.g., Morris & Carstea, 1998).  Of these two diagnostic 
techniques, the filipin test has higher rates of sensitivity and specificity (Vanier & Millat, 
2003).     
The large age range for both the onset and diagnosis of NPC, coupled with a 
broad clinical spectrum, creates significant challenges for researchers investigating the 
natural history of this disease.  The classical onset of neurological symptoms begins in 
the late-infantile and juvenile years, with death occurring in the second decade (e.g., 
Garver et al., 2007).  However, the age of presentation, and the subsequent age of 
diagnosis, may range from the perinatal period to adulthood (e.g., Vanier & Millat, 
2003).  Given this variability, some researchers have suggested a further breakdown of 
the NPC phenotype to subgroups of neonatal, childhood, or adult presentation (Imrie et 
al., 2007).    
The initial clinical symptoms of NPC may be neurological or psychiatric (Vanier 




neonatal jaundice and early-childhood hepatosplenomegaly.  The hallmark dysfunction is 
neurological, however, and can include cerebellar ataxia and motor impairment, speech 
and swallowing disorders (e.g., dysarthria, dysphagia,), dystonia, hypotonia, cataplexy, 
and seizures.  Neurological symptoms may progress to states of psychosis and dementia.  
Demyelinating polyneuropathy has been reported in several cases of NPC, and is 
purported to have a higher incidence within the disease than is currently recognized 
(Zafeiriou et al., 2003).  The finding of supranuclear vertical gaze palsy is practically 
pathognomonic for NPC (e.g., Fink et al., 1989; Uc, Wenger, & Jankovic, 2000; 
Zafeiriou et al., 2003), and may be an early indication of neurological involvement when 
it is detected.  Additional oculomotor dysfunction secondary to specific brainstem 
neuropathology has been reported (Solomon, Winkelman, Zee, Gray, & Büttner-Ennever, 
2005). 
Auditory function in NPC 
In light of the systemic nature of NPC, it is doubtful the auditory system remains 
unaffected during the course of this disease.  Indeed, there are limited accounts of 
auditory manifestations in NPC; however, reports of auditory function in any of the NPD 
variants are sparse.  The overwhelming majority of NPC case studies fail to evaluate 
auditory function unless the patient specifically presented with complaints of hearing 
loss.  Even in such cases, comprehensive audiological evaluations were typically 
deferred, or not reported.  It is clear that this aspect of the phenotype has not been 
thoroughly examined.  Moreover, a pediatric, neurologically compromised population 
poses significant challenges to obtaining behavioral auditory assessments, and it is likely 




suggests that the limited auditory data published to date may underrepresent the actual 
auditory phenotype in NPC. 
 A review of previously reported auditory manifestations in NPC reveals a modest 
collection of case reports and natural history studies. Often these are limited or vague 
reports of auditory dysfunction, such as the description of an 18-month-old African child 
with NPD, type unknown, who displayed, “marked delay in motor, social, speech, and 
hearing progress …” (Singer, Lowe, & Cmelik, 1972).  Schneider et al. (2001) reported a 
33 year old woman with adult onset NPC who had normal, “acoustically… evoked 
potentials …”, and Palmeri and colleagues (2005) described a 16 year old male with NPC 
whose ABR showed increased I-V and III-V interpeak latencies bilaterally, although no 
additional information was provided. 
 Sévin et al. (2007) published a comprehensive review of adult-onset NPC, in 
which they reported findings from 13 unrelated patients.  On average, the age of onset of 
neuropsychiatric symptoms was 25 years and the age at death was 38.  Detailed magnetic 
resonance imaging (MRI) showed atrophy in, among other locations, the cortex, 
cerebellum, corpus callosum, and brainstem.  Three (23%) of their patients were 
identified as having “perceptual deafness,” a finding the authors suggest indicates deep 
brain involvement.  In two of these cases, “deafness” was a premonitory symptom in 
childhood preceding the onset of neurological signs.  The hearing metric was not 
identified and standard descriptions of hearing (e.g., type, degree) were not provided.  
One patient presented with, “an unexplained perceptive hypoacousia.”   Another had a 
family history of “deafness” that followed a recessive inheritance pattern.  Hearing loss in 




These three case reports of adult-onset NPC that include auditory manifestations 
(Sévin et al., 2007) are a unique addition to the literature, especially considering that in 
two of three cases hearing loss was an early-onset symptom.  However, specific 
conclusions about site of lesion and auditory pathophysiology cannot be made due to a 
lack of detail in how hearing was measured and use of the generic label “deafness” 
applied to all three cases.        
Garver et al. (2007) presented natural history data collected by questionnaire that 
described clinical and overall health in a cohort of patients with NPC.  The 83-question 
survey was mailed to 136 families affected by NPC living in the United States, of whom 
87 (64%) responded.  Parents/caregivers and physicians of individuals with the disease 
provided the responses.  The average age of diagnosis for NPC was 10.4 years and the 
average age of death was 16.2 years.  Although not stated directly, this implies most of 
the participants in this study presented with the classical onset of NPC.  In a section on 
general medical and developmental problems experienced by affected individuals, three 
questions asked specifically whether the child with NPC has hearing problems, ringing in 
the ears, and/or dizziness/vertigo complaints.  “Hearing problems” were reported in 13 
(15%) of the respondents, “ringing in the ears” in one (1%), and “dizziness or vertigo” in 
five (6%).  Seventy-five (87%) respondents reported at least slight-to-moderate difficulty 
with “Language,” with more than half describing severe or difficult problems; however 
no attempt was made to correlate these communication issues with hearing impairment. 
The data presented by Garver et al. (2007) are another indication that auditory 
manifestations are a part of the global NPC phenotype, and that hearing loss may be an 




necessary to make conclusive statements regarding diagnosis and etiology.  Many 
patients without neurological involvement who have mild hearing loss are unaware of it, 
and consequently, underreport the symptom (e.g., Reilly, Troiani, Grossman, & 
Wingfield, 2007).  It seems probable these individuals would have been limited in their 
ability to report subjective auditory dysfunction, and that the data presented may 
underestimate the frequency and, perhaps, the severity of the problem.     
Several earlier reports of auditory dysfunction in patients with NPC provide 
somewhat greater detail than those discussed previously.  Aisen, Rapoport, and Solomon 
(1985) published a report of ABR findings in two brothers under the age of four years 
with NPC.  Neither sibling presented with any auditory complaints or clinical evidence of 
brainstem dysfunction.  ABRs were obtained with moderate stimulus intensity (“60 
dBSL”) at a click rate of 11 per second.  Both brothers showed prolonged I-III interwave 
latencies, a normal absolute latency for wave V, and all other interpeak latencies within 
normal limits.  In spite of disparate neurological manifestations and overall disease 
severity between the two brothers, the ABR results for both boys were remarkably similar 
and suggested a delay in the neural conduction time between the auditory nerve and the 
cochlear nucleus.  The authors suggest it is possible that the delay extends as far along in 
the system as the superior olivary complex. 
Fink et al. (1989) analyzed neurological symptomatology in 22 patients with 
NPC, including the auditory phenotype.  Their population consisted of 10 males and 12 
females ranging in age from 18 months to 27 years.  Twenty-one of these patients were 
given audiological evaluations that included behavioral assessment for speech and pure-




additional methodological details provided on how auditory data were collected.  They 
reported a pervasive high-frequency hearing loss in 14 individuals that was presumably 
sensorineural in nature.  Although tympanometry was unremarkable, abnormal (i.e., 
absent or elevated) acoustic reflexes and/or positive acoustic reflex decay were observed 
in 17 of 21 patients.  ABR abnormalities included eight individuals with prolonged I-V 
interpeak latencies, and three individuals with prolonged I-III interpeak latencies.  The 
authors note that 10 people presented with an abnormal ABR, but it is unclear whether 
these 10 individuals included those with prolonged interpeak latencies already presented, 
or if they represent other patients with abnormalities.  Additional specific ABR findings 
were not described.  Although Fink and colleagues offer one of the few audiologic 
profiles in patients with NPC, their report is limited in its detail and scope.  As a result, it 
is difficult to draw concrete conclusions beyond a very general description of the 
phenotype. 
A report by Pikus (1989) is the only published account focusing solely on 
comprehensive audiological findings in patients with NPC.  This brief document 
describes a cohort of 28 patients with NPC ranging in age from two to 37 years.  
Audiological assessment included behavioral evaluation of hearing using speech and 
pure-tone stimuli, tympanometry and acoustic reflex testing, and measurement of the 
ABR.  No specific methodological details or stimulus/recording parameters were 
provided.   
Twenty-one (75%) of 28 patients exhibited hearing loss of varying degrees, which 
was almost always confined to the high frequency test region.  While the type of hearing 




in all patients.  The author notes the hearing loss “appears to progress over time and with 
increasing severity of somatic symptoms,” however there was no explanation of the basis 
for this statement.  Specifically, it is unclear whether the conclusion is made from 
longitudinal data, which were not reported, cross-sectional analysis, or anecdotal 
observation. 
ABR findings were abnormal in 15 patients (53%) and, although the 
abnormalities observed across the population were labeled as “diverse,” specific 
descriptions are lacking.  Prolonged I-V interpeak latencies, overall dysmorphic 
waveforms, and normal V/I amplitude ratios are the only details provided.  A prevalent 
finding in this sample was abnormal acoustic reflexes, observed in 23 (85%) patients, and 
it is described as, “an early disturbance.”  The author concludes that, given the age of this 
cohort, abnormal acoustic reflex findings may serve as an early indication of NPC onset.  
However, the age range of this group (2 to 37 years) does not suggest they represent an 
especially young cohort of patients with NPC considering the classical late infantile to 
juvenile onset of the disease.  In order to conclude that aberrant acoustic reflex findings 
are an initial symptom, there should be data to support that the cohort in question is 
actually in the early stages of the disease.  This is not likely to be the case in the 
population reported by Pikus, however there are no data provided to dispute conclusively 
or confirm this claim.   
Higgins et al. (1992) reported similar audiological findings to Fink et al. (1989) 
and Pikus (1989).  They observed increased ABR latencies and abnormal acoustic 
reflexes in their sample of NPC patients.  While the size of each cohort reported by 




originated from the same institution (National Institutes of Health), the findings and 
manner in which they are reported are strikingly similar, and at least one individual 
(Pikus) who is an audiologist is an author on all three studies.  Thus, it is not clear that 
these reports represent three separate samples of individuals with NPC.  An initial review 
of the audiology literature on NPC may lead some to conclude that ABR abnormalities 
and aberrant acoustic reflex findings are a pervasive finding in the disease given their 
consistent presence across three distinct publications.  If, in fact, there is overlap between 
the reported samples, it would suggest that replication of these findings in additional 
independent cohorts is necessary.   
  It is worth noting a small collection of articles describing histological analyses in 
the temporal bones of patients with NPD, most likely type A.  Druss (1932) reported 
proliferation of Niemann-Pick cells in the auditory nerve and degeneration in the ganglia 
of the seventh and eighth cranial nerves.   Oppikofer (1935) reported no anatomical 
abnormalities in the inner ear of a child with severe hearing loss and concluded the 
origins of the loss were based on some central dysfunction.  Bachor et al. (1997) 
described the temporal bones of three patients, aged 6 months, 7 months, and 2.5 years at 
the time of death, all with NPA.  Light microscopy revealed abnormal lipid storage in the 
ganglion cells and changes in the organ of Corti, including alterations in the stria 
vascularis and missing or deformed hair cells.  Behavioral and electrophysiological 
evaluations of hearing were not performed on any of the patients.  While these studies 
describe the histopathological findings in the temporal bones of patients with NPA, they 




nothing else, they offer further evidence of pathological invasion of the inner ear and 
auditory system in a lipid storage disease. 
Although the research describing hearing in humans with NPC is limited, auditory 
dysfunction does appear to be part of the disease process.  A clear picture of the auditory 
manifestations is still missing, however, and there have been no definitive reports on 
whether the auditory phenotype is progressive, despite the known neurodegenerative 
characteristics of the disorder.  If a clear and consistent phenotype emerges, it is possible 
the auditory system may become a useful benchmark for future pharmacological and 
therapeutic interventions for NPC.  Patterson, Vecchio, Prady, Abel, and Wraith (2007) 
published findings from a therapeutic study in which hearing sensitivity was one outcome 
measure.  The purpose was to evaluate the efficacy and potential side effects of the 
experimental treatment miglustat (Zavesca), a small iminosugar that can cross the blood-
brain barrier, on patients with NPC.   They monitored several clinical markers, including 
hearing sensitivity.  Auditory acuity was based on the ability of the participant to hear 
either a ticking watch or a Manchester rattle, and a 256 Hz tuning fork.  Each device was 
“held at 30 cm or less from the external auditory canal.”  If the patient was able to hear 
the sound source at 30 cm they were classified as normal.  Any distance less than 30 cm 
was abnormal, unless they were unable to hear the sound source at all, in which case they 
were labeled “deaf.”   
By these definitions, auditory acuity at baseline prior to treatment was normal in 
31 out of 40 (78%) ears in the treatment group receiving miglustat.  A control group of 
patients with NPC not receiving treatment was tested and hearing was reportedly normal 




treated with miglustat, whereas two patients in the control group eventually presented 
with “deafness.”   
The measurement of hearing sensitivity in this study is invalid, rendering it 
useless for either clinical or research purposes.  However, it raises the question of how 
the results would have been interpreted if the group receiving miglustat exhibited 
significant changes in hearing.  With no basic understanding of the natural history of the 
auditory phenotype, it is impossible to discern what is an expected change due to disease 
progression and what may be a direct adverse event from the drug.  If the conclusion 
were the latter, the development and proliferation of a potentially safe treatment may be 
delayed.   
While the audiological limitations of this study are obvious, the authors note that 
hearing impairment in NPC is easily overlooked and an important aspect in quality of 
life.  These data, at the very least, provide additional evidence of auditory dysfunction in 
NPC and appear to be the first attempt in which hearing sensitivity was used as a 
benchmark for monitoring intervention in this disease.  A clear understanding of the 
natural history of the auditory phenotype in NPC will only improve the efficacy of future, 
similar endeavors.      
Summary    
The purpose of experiment one is to evaluate further the auditory phenotype in 
humans with NPC.  There are a number of remaining obstacles to understanding this rare, 
devastating disease, including established clinical markers for its onset and progression, 
and there is no effective treatment or cure; interventions at this time are focused on 




dysfunction is a part of the NPC phenotype, and the case has been made that it is likely 
an underreported manifestation.  The natural history of the auditory phenotype, however, 
remains unknown, which hinders prognostic counseling for patients and families, and the 
etiology of the hearing loss is unclear, although preliminary data suggest it may be 
complex and widespread throughout the auditory system.   
Research Questions and Hypotheses 
The overarching question is whether or not the pathophysiological processes of 
NPC detrimentally impact the auditory system in humans and, if so, in what ways?  
Research Questions  
 
1. Do patients with NPC exhibit peripheral hearing loss and/or evidence of central 
auditory nervous system (CANS) dysfunction? 
a. If hearing loss exists, is it localized to the conductive or sensorineural 
pathway? 
b. If CANS dysfunction exists, can it be localized to the auditory brainstem? 
c. Is auditory system dysfunction observed consistently in a sample of 
patients with NPC? 
1.) Is auditory dysfunction present in the majority of this sample? 
2.) Is auditory dysfunction stable, progressive, or fluctuating among 
this sample? 
3.) If variability exists in the presence/absence or natural history of 
auditory dysfunction, are there individual factors that contribute 
to this variability, specifically: age of disease onset (defined as 




duration of disease, gender, or the use of the experimental 




It is hypothesized that patients with NPC will exhibit both peripheral hearing loss 
and evidence of CANS dysfunction, and that auditory manifestations will be consistent 
across the majority of a sample of patients with the disease.  NPC is associated with CNS 
and brainstem pathology, as well as neuropathy in multiple peripheral nerves and 
dysfunction in CNS myelin (Vincent et al., 2003).  This suggests a high potential for 
abnormal retrocochlear findings in patients with NPC.  A mixed peripheral/CANS site of 
lesion may manifest as elevated air-conduction and bone-conduction behavioral 
thresholds, elevated acoustic reflex thresholds and/or abnormal acoustic reflex 
adaptation, absent otoacoustic emissions or a loss of transient-evoked otoacoustic 
emission (TEOAE) suppression over time, or increased neural conduction time on the 
ABR relative to published normative data (Issa & Ross, 1995; Joseph, et al, 1987).  No 
significant conductive pathologies are anticipated in this cohort.  
It is hypothesized that auditory dysfunction will be progressive in patients with 
NPC, in light of the well-established progressive nature of the disease, although it is 
unclear if this will manifest over the experimental time frame ranging from zero months 
to four years of follow-up.  NPC is a highly pleiotropic disease, which suggests 
influences from undiscovered genetic and environmental modifiers.  These potential 




data in neurologically compromised participants, may make the progressive nature of the 
auditory phenotype difficult to determine in a human population.      
It is hypothesized that no significant effects of independent variables on hearing 
will be observed in this group, specifically: age of disease onset (defined as the age at 
first reported symptom), age at the time of test, duration of the disease, gender, or the use 
of miglustat for disease treatment.  Both age and gender have been shown to effect 
hearing (e.g., Pearson, et al., 1995) and should be considered when interpreting auditory 
data.  However, the age of NPC disease onset can range from the perinatal period to 
adulthood (Vanier & Millat, 2003), suggesting this variable and variables related to it 
(e.g. duration of disease) are unlikely to correlate strongly with auditory function. 
Similarly, gender effects are not an established part of the NPC phenotype, and, 
consequently, this variable is not hypothesized to significantly affect experimental 
auditory outcomes.  Miglustat is an enzyme inhibitor currently approved by the Food and 
Drug Administration to treat Gaucher disease, another lipid storage disorder.  Some 
patients with NPC elect to use miglustat, although off-label treatment for this disease is 
experimental.  Its use in this cohort cannot be controlled and will vary between patients.  
Because of this variability, and because no robust empirical effects of miglustat for 
treating NPC have been reported, it is hypothesized that it will have no significant effect 










Participants.  Participants were those patients with NPC disease admitted to the NIH 
Clinical Center for evaluation in the ongoing protocol entitled, “Evaluation of 
Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, type C” 
(NCT00344331).  This protocol was approved by the Institutional Review Board of the 
National Institute of Child Health and Human Development (NICHD) and began in June 
2006.  Recruitment for the NIH protocol is through both parent and professional 
organizations, and handled by the principal investigator, Dr. Forbes Porter, and under the 
auspices of the NICHD.  The Institutional Review Board of the University of Maryland 
College Park approved this work (07-0675, PAS# 1868.3). 
Once a patient was enrolled in the NIH protocol, they were eligible for participation 
in this experiment.  Based on the NIH inclusionary and exclusionary criteria, all patients 
with an established diagnosis of NPC (biochemical or molecular) were considered for this 
study.  Patients were excluded if they could not travel to the NIH because of their 
medical condition or were too ill to be cared for at home.  Patients with rapidly 
progressive neonatal cholestasis were also excluded. Patients with stage 4 disease status 
(non-ambulant with vegetative disturbances) were not enrolled.  Patients were excluded if 
they were pregnant (a negative urine pregnancy test was required for any menstruating 
female before participation in this study and at each NIH Clinical Center admission).  
Otherwise, patients of any age, sex, or ethnic background were eligible for this study.  




Equipment.  Age- and ability-appropriate behavioral audiological data, as well as 
electrophysiological data obtained in unsedated patients (tympanometry, OAEs, and 
ABR), were collected in double-walled sound suites in accordance with the American 
National Standards Institute criteria (ANSI, 2010).  For patients who were unable to 
cooperate for unsedated electrophysiological analyses, sedated testing took place in either 
an operating room or a special procedure room, during which sedation was administered 
and monitored by licensed anesthesia personnel, and noise levels were kept to a 
minimum.   
Behavioral audiological data were collected using a Grason-Stadler (GSI-61) 
diagnostic audiometer.  Middle ear function was measured using an acoustic immittance 
unit (GSI Tymp Star, GSI-33).  OAEs were measured using an Otodynamics Echoport 
Otoacoustic Emission System supported by ILO V6 Clinical OAE software on a Dell 
laptop computer.  ABR data were collected using Audera software and supported on a 
Dell laptop computer.     
Procedure.  Details of the entire NIH protocol entitled, “Evaluation of 
Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, type C” 
(NCT00344331) are not included in this document but are available for review.  The co-
chair for this dissertation, Dr. Carmen Brewer, and the student investigator, Kelly King, 
are associate investigators on the NIH protocol.  
Admissions (including hospital stay) at the NIH lasted approximately 4-5 days 
and occurred every six months or once per year, as determined by Dr. Forbes Porter.  
Numerous clinical, biochemical, and radiological evaluations took place during the 




Multiple considerations were made when selecting an appropriate test battery to 
determine the natural history of this disease.  Evidence exists for widespread dysfunction 
in the auditory system, potentially involving numerous peripheral and central sites.  Thus, 
an extensive test battery was required.  It was also imperative to consider the ability and 
neurological status of the population in question.  Depending on the age of onset and 
neurological involvement in an individual at the time of testing, the acquisition of 
behavioral audiological data can be limited, if not impossible.  Furthermore, in patients 
with significant neurological involvement, obtaining certain types of electrophysiological 
data may also be compromised.   
With these issues in mind, the following describes the test battery employed to 
define the auditory phenotype in NPC.  It should be noted that the acquisition of each 
measure was not possible in all patients.  Justification for each test, as well as procedural 
methodology, is included. 
 
1.  Evaluation of middle ear function and the acoustic reflex arc (acoustic 
immittance): tympanometry, ipsilateral and contralateral acoustic reflexes, and 
acoustic reflex adaptation (decay). 
These are quick, non-invasive measures that provide critical information 
on the health and integrity of the middle ear system and the acoustic reflex arc, 
which involves cranial nerves VII and VIII, as well as the cochlear nuclei, 
superior olivary complex, and facial motor nuclei.  These tests provide important 




Procedure: Otoscopy was performed prior to testing.  A single-frequency (226 
Hz) tympanogram was obtained to measure tympanometric peak pressure (TPP), 
ear canal volume, and peak-compensated static admittance.  Ipsilateral and 
contralateral acoustic reflex thresholds were determined at stimulus frequencies of 
500, 1000, and 2000 Hz.  Acoustic reflex adaptation was evaluated by presenting 
a pure-tone (500, 1000 Hz) at a level 10 dB above the acoustic reflex threshold for 
10 seconds in the contralateral stimulus condition.  The intensity of the test 
stimulus did not exceed 110 dB HL in either of these measures.   
The acoustic reflex threshold was defined as the lowest intensity level of a 
stimulus that elicited a ≥ 0.02 mmho decrease in admittance, and which replicated 
in order to be considered a valid reflex.  If no repeatable acoustic reflex was 
measured at these levels, the reflex was considered absent.   
Acoustic reflex adaptation is a reduction in the magnitude of change in admittance 
during a 10 second period of stimulus presentation.  This was considered positive 
(abnormal) if the change in admittance decreased by > 50% during the 10 second 
stimulus presentation, indicating failure of the stapedius muscle to maintain its 
contraction over time.   
2.  Pure-tone thresholds and suprathreshold speech recognition performance  
A comprehensive audiological evaluation includes the behavioral pure-
tone audiogram.  Accurate and thorough interpretation of objective 
electrophysiological results is contingent on these data, and the audiogram is a 




Suprathreshold speech recognition performance is also a standard 
component of the audiological evaluation to establish the possible effects of 
reduced audibility and signal distortion associated with the hearing loss on speech 
understanding.  Extremely poor speech recognition performance that is 
disproportionate to the degree of peripheral hearing loss may be an indication of a 
retrocochlear site of lesion.   
Procedure: Whenever possible, ear-specific data were obtained. An attempt was 
made to measure pure-tone air-conduction thresholds at .25, .5, 1, 2, 3, 4, 6, and 8 
kHz, and bone-conduction thresholds at .25, .5, 1, 2, 3, and 4 kHz.  Threshold was 
considered the lowest intensity at which a person was able to detect correctly the 
stimulus 50% of the time upon ascending runs.  Speech recognition/detection 
thresholds (SRT/SDT) to spondee words, and suprathreshold (e.g., 40 dB SL re: 
SRT, and 85 dB HL) word recognition using age-appropriate monosyllabic word 
tests (Northwestern University Test #6, NU-6; PBK-50; Word Intelligibility by 
Picture Identification, WIPI) were determined via monitored live voice, which 
allowed the examiner the ability to quickly engage fatiguing patients in an effort 
to extend the test session.   
3.  Otoacoustic emission (OAE) testing: distortion product (DP) OAEs, as well as 
transient evoked (TE) OAE suppression.   
OAEs are low-level acoustic signals that originate in the cochlea; they can 
be recorded with sensitive microphones in the external auditory canal.  OAEs can 
occur spontaneously, in the absence of an eliciting stimulus, or they can be 




tones of different frequencies (f1 and f2) presented simultaneously to the cochlea, 
and provide mid- and high-frequency (~1-8 kHz) information on the functional 
integrity of the cochlear outer hair cells.  TEOAEs are often evoked using a click 
stimulus that elicits a broadband response up to approximately 4 kHz from the 
basilar membrane.  This broadband response is then analyzed in half octave 
frequency bands. Suppression of the TEOAE response (level) can be observed 
when a contralateral masker is presented to the non-test ear.  This is a non-
invasive window into the function and integrity of central locations along the 
auditory pathway that regulate OAE production, specifically, the olivocochlear 
efferent system. 
Procedure:  Due to a risk of patient fatigue or lack of cooperation, emphasis was 
placed on obtaining DPOAEs first because they provide frequency-specific 
information across a broad range, from 842 to 7996 Hz.  Following in situ 
calibration in the ear canal, DPOAEs were measured by varying f2 in one-quarter 
octave decrements from 7996 to 842 Hz.  In order to achieve a robust 2f1-f2 
emission, an f2/f1 ratio of 1.2 (e.g., Abdala, 1996) was used, with L1 and L2 set 
at 65 dB SPL and 55 dB SPL, respectively (e.g., Stover, Gorga, Neely, Montoya, 
1996).  A minimum of three full frequency sweeps was accomplished prior to test 
termination, when possible.  An emission was considered present if the DPOAE 
level was > 6 dB above the noise floor. 
In cooperative patients who were able to complete additional testing, TEOAE 
suppression was attempted.  TEOAEs were first recorded with a nonlinear 




second (e.g., Stover & Norton, 1993).  In the nonlinear mode of the ILO software,  
the first few milliseconds of the response are removed from analysis to ensure no 
stimulus energy is contained within the response, consequently mitigating risk of 
stimulus artifact contamination.  A stimulus check-fit was performed in situ in the 
ear canal prior to TEOAE recording to confirm an adequate stimulus was present.  
A total of 260 artifact-free averages were obtained to a broad-band stimulus prior 
to test termination.  A nonlinear TEOAE was considered present if the signal-to-
noise ratio (SNR) was ≥ 6 dB.  If no nonlinear TEOAE was present, further 
testing for TEOAE suppression was halted. 
If TEOAEs were present for at least one half-octave frequency band, and 
assuming the patient remained cooperative, measurement of TEOAE suppression 
was attempted.  This was performed by placing a probe in the contralateral ear 
with a broadband white noise masker set to 65 dB SPL, while a linear click 
stimulus was presented to the test ear at 60 dB SPL.  In the linear mode, none of 
the response window is removed following averaging, and thus contain some 
stimulus energy in the TEOAE; however, the linear mode is appropriate for 
TEOAEs at lower stimulus levels and is ideal for measuring suppression of the 
response, when small changes in TEOAE amplitude are expected. The delivery of 
stimuli and masker noise alternated between noise-on and noise-off conditions.  
Specifically, the stimulus alone was presented for ten seconds (noise-off), after 
which the noise was presented concurrently with the stimulus for ten seconds 
(noise-on).  This interleaved presentation of noise-on, noise-off recording 




amount of overall TEOAE suppression across frequency bands to contralateral 
stimulation was calculated by subtracting TEOAE amplitude during the noise-on 
condition from the amplitude recorded during the noise-off condition.  If a 
difference in amplitude between conditions of greater than or equal to 1 dB (e.g., 
Berlin, Hood, Hurley, & Wen, 1994) was observed, then suppression was 
considered present.  Given the variability of suppression across individuals (De 
Ceulaer, et al., 2001), absence of TEOAE suppression was considered 
pathological only in cases when suppression was previously present.   
4.  Auditory Brainstem Response (ABR).  
The ABR is an evoked electrical potential of neural origin, generated from 
the distal portion of the auditory nerve through the level of the lower brainstem in 
response to acoustic stimulation.  Like other auditory evoked potentials (AEPs), it 
is recorded by computer-controlled signal summation and averaging techniques 
used to distinguish synchronous neural activity from random background 
electrical activity.   The ABR can be recorded from a number of species and is 
routinely used in the diagnosis and management of auditory dysfunction in 
humans.  Responses can be generated and amplified with broadband stimuli, such 
as clicks, or more frequency-specific tone bursts.  Signals are bandpass filtered 
(e.g., 300 to 3000 Hz) and multiple recordings, or sweeps, are conducted to 
generate an averaged waveform response (e.g., Burkard, Shi, & Hecox, 1990). 
Brainstem dysfunction is often associated with NPC and there is potential 
for involvement of the auditory nerve and demyelination.  This is a useful test in 




already known about the pathophysiological manifestations of NPC.  In the event 
that behavioral testing is prohibited (because of patient factors), the ABR, in 
conjunction with other measures, may be used to infer hearing sensitivity. 
Procedure: Neuro-otological ABRs were attempted on every patient in the 
protocol.  For those patients who were able to sit quietly during testing, ABRs 
were obtained while they were awake, resting quietly, and in a seated or 
recumbent position.  All other patients had ABRs performed while they were 
sedated and in a supine or lateral position.  Disposable surface electrodes were 
placed in an Fz to earlobe (or mastoid) configuration, with a grounding electrode 
placed at Fpz.  Broadband click stimuli were presented via insert earphones (Ear 
Tone ER-3A).  Neuro-otologic ABRs were obtained using a high-level (85 or 95 
dB nHL) stimulus intensity.  Single polarity traces using negative versus positive 
polarity clicks (rarefaction and condensation, respectively) were acquired using a 
click rate of 8.3 per second.  Test paradigms including a fast click rate of 63.3 per 
second (85/95 dB nHL, rarefaction) and a lower intensity stimulus of 65 dB nHL 
(8.3/second, rarefaction) were recorded to further establish neural integrity (Hall, 
1992; Hood, 1998).  A minimum of 1000 stimulus presentations were averaged 
for each ABR test run, and every condition was replicated to determine 
repeatability of the waveform.  
A benefit of using single polarity clicks versus alternating polarity stimuli is that 
they allow the examiner to distinguish cochlear from neural responses.  
Specifically, there is potential observation of the cochlear microphonic (CM) 




occurs when the basilar membrane is displaced, believed to originate from 
depolarization of the cochlear hair cells.  This response will mimic the polarity of 
the incoming stimulus, whereas a neurogenic response will maintain its polarity 
regardless of changes to stimulus polarity.  The ABR is not the ideal recording 
paradigm with which to observe the CM; therefore, absence of a CM during the 
ABR is not considered pathologic.  However, it is useful to know when a CM is 
present so that cochlear responses are not inadvertently confused with those that 
are believed to be neurogenic in nature.      
Two control runs were performed on each ear during ABR data collection.  The 
first was a 0 dB nHL (8.3/second, rarefaction) stimulus, and the second was an 
85/95 dB nHL (8.3/second, rarefaction) stimulus with the tubing of the insert 
earphone clamped.  These control runs established the quality of the experimental 
traces by ensuring they were free from electrical and or physiological artifacts, 
and aided in the quantification of results. 
Neuro-otologic ABRs were evaluated based on the presence of waves I, III, and 
V.  Absolute and interpeak latencies of high level, low rate (85/95 dB nHL, 
8.3/sec) stimulation were recorded, and overall waveform morphology was 
assessed.  Responses obtained with faster click rates and lower intensity 
stimulation were evaluated to determine if there was an appropriate degradation 
of the response and prolongation of wave V, which helped ensure the response 
was neural in nature.  
The presence/absence of cochlear microphonics was evaluated by comparing 




(85/95 dB nHL) and low stimulus rate (8.3/second).  Cochlear responses mimic 
the polarity of the incoming stimulus and will therefore reverse with changes in 
stimulus polarity.  These are distinguished from neural responses that do not 
invert with changes in stimulus polarity.        
 
The total audiologic evaluation was completed in approximately two hours.  The 
order in which tests were administered loosely corresponds to the order in which they 
were presented within this document; however, this was ultimately dependent on patient 
cooperation and fatigue.  The initial test ear was randomized within and across patients.  
The methods and stimuli used for behavioral data collection varied depending on the age 
and ability of the participant, which is standard for audiologic evaluations.  Indeed, the 
ability of this population was highly variable given the early onset of the disease and the 
progressive neurological involvement, including psychosis and/or dementia.  The test 
technique used during the baseline evaluation was maintained as the test technique for all 
follow-up visits, when possible.  
Acoustic admittance measures, OAEs, and ABR are inherently objective 
measures of auditory function that can be administered consistently.  Behavioral 
audiometry proved more difficult to administer in a consistent manner and to obtain 
complete results during each test session because either a patient was too young or too 
severely affected to complete the exam.  In those patients for whom no behavioral 
hearing data could be obtained, Auditory Steady State Response (ASSR) measures were 




clinical intervention.  The ASSR was obtained while the patient was sedated for 
additional procedures (e.g., imaging studies, Lumbar puncture). 
Assessment of auditory midbrain and cortical function was not included in this 
protocol.  Formal assessment of central auditory function would not be possible to obtain 
in the vast majority of patients with NPC while they are awake and would be unreliable 
or unattainable in a sedated patient.  If these data could be obtained in a small number of 
patients with NPC, it would likely not be possible to extrapolate findings meaningfully to 
the larger population of patients.  
Statistical Analyses.  Data were maintained and analyzed using Microsoft Excel, 
the Statistical Package for Social Science Software (SPSS, v15), and the Proc MIXED 
SAS 9.1 software packages.  Experiment one was a single-group design for analysis on 
an individual level and across the group of NPC patients.  For those individuals with 
longitudinal data, their baseline audiological exam served as the reference to which all 
subsequent evaluations were compared.   
To identify potential independent variables that may affect hearing, a mixed 
model linear regression analysis was used to evaluate effects of gender, use of the 
experimental therapeutic drug miglustat, and age.  Three variables related to age were 
examined: age at disease onset (defined as age at first symptom), age at baseline testing, 
and time from disease onset.  Because all three age variables are related, they were not 
included in the model together at any one time, but rather evaluated independently and 
with other non-age-related variables.  The dependent variables to quantify hearing were 
pure-tone averages: .5/1/2 kHz, .5/1/2/4 kHz, .25/5 kHz, and 4/8 kHz. For this analysis, 




 For patients less than 6 years of age, tympanometry was considered normal if the 
static admittance value was between 0.2 mmhos and 0.8 mmhos, if the tympanometric 
pressure peak was between -140 and +15 daPa, and the equivalent ear canal volume (Vec) 
was between 0.4 to 1 cm3.  For patients 6 years of age and older, tympanometry was 
considered normal if the static admittance value was between 0.3 mmhos and 1.4 mmhos, 
if the tympanometric pressure peak was between -85 and 0 daPa, and the equivalent ear 
canal volume (Vec) was between 0.6 to 1.5 cm3 (Margolis & Heller, 1987).  Ipsilateral 
and contralateral acoustic reflexes were considered normal if they were elicited at levels 
equal to or less than the 90th percentile published by Gelfand, Schwander, and Silman 
(1990).  Acoustic reflex decay was considered negative (normal) if the change in 
admittance did not decrease by > 50% during stimulus presentation over a 10 second 
period of time.  These measures were analyzed as categorical data and defined based on 
normal and abnormal criteria.   
Pure-tone audiometric data were evaluated and the type, degree, and configuration 
of hearing loss were determined from criteria described by King et al. (2007) in Table I.  
Individual and mean data across the cohort were analyzed.  Longitudinal change in 
hearing was evaluated individually, and cross-sectional data were used to evaluate 
hearing and age-related change. 
Suprathreshold word recognition scores were collected initially to compare to the 
Speech Intelligibility Index (SII, ANSI S3.5-1997), based on the Articulation Index (AI, 
French & Steinberg, 1947).  However, the small number of individuals for whom these 
data could be collected, the large range of patient performance, and the variation in the 




the SII to this data set.  In those patients able to provide word recognition scores at two 
presentation levels (moderate and high dB SL re: SRT), a rollover index was calculated 
from the phonetically balanced (PB) NU-6 word lists to differentiate cochlear versus 
eighth nerve lesions (RI = PBmax - PBmin / PBmax, where PBmax is the highest word 
recognition score for an ear and PBmin is the lowest).  A RI of > 0.25 (Bess, Josey, & 
Humes, 1979) was considered as a positive sign for a retrocochlear lesion. 
The presence or absence of DPOAEs and TEOAE suppression were documented 
in each participant and were used to determine site of lesion within an individual.  Mean 
(SD) DPOAE level data for the group across test frequencies was calculated.  Presence 
and absence of DPOAEs (6 dB SNR) were determined in those individuals without 
evidence of middle ear disease. TEOAE suppression was categorically analyzed as either 
present or absent, and the absence of TEOAE suppression was only considered 
pathological when it was present previously in an individual.       
Interpretation of ABR absolute and interpeak latencies was based on normative 
data published by Joseph, et al. (1987) for those greater than 3 years of age and Issa and 
Ross (1995) for those less than or equal to 3 years.  Descriptive statistical group data, 
including categorical interpretation (normal versus abnormal) for absolute and interpeak 









Table I.  Operational definitions for normal hearing and type, degree, and configuration 
of hearing loss. 
Classification  Criteria 
*Type Normal Average AC thresholds ≤ 20 dB HL 
No A-B gaps > 10 dB 
 
 Conductive Average BC thresholds ≤ 20 dB HL 
Average A-B gap ≥ 15 dB 
 Sensorineural Average BC thresholds > 20 dB HL 
Average A-B gaps ≤ 10 dB 
 
 Mixed Average BC thresholds > 20 dB HL  




Does not meet above criteria 
   
†Degree Normal ≤ 20 dB HL 
 
 Mild > 20 and ≤ 40 dB HL 
 
 Moderate > 40 and ≤ 70 dB HL 
 
 Severe > 70 and ≤ 95 dB HL 
 
 Profound > 95 dB HL 
   
Configuration Normal All PT thresholds from 250-8000 Hz ≤ 20 dB 
HL 
 Flat < 15 dB difference between all thresholds 
from 250-8000 Hz 
 LF-Ascending ≥ 15 dB difference between LF and better HF 
thresholds 
 Mid-Frequency U-Shaped ≥ 15 dB difference between worst mid-
frequency (1000-2000 Hz) thresholds and 
those of higher- and lower-frequencies 
 HF-Gentle 15-29 dB difference between mean thresholds 
of 500 and 1000 Hz and mean thresholds of 
4000 and 8000 Hz 
 HF-Sharp ≥ 30 dB difference between mean thresholds 
of 500 and 1000 Hz and mean thresholds of 
4000 and 8000 Hz 




Note. AC, air conduction; BC, bone conduction; A-B, air-bone; PT, pure-tone; LF, low-
frequency (250-500 Hz); HF, high-frequency (4000-8000 Hz). * Type of hearing loss was 
determined based on three-frequency (500, 1000, 2000 Hz) PT averages for AC and BC.  
† Degree of hearing loss was based on a four-frequency (500, 1000, 2000, 4000 Hz) PT 
AC average. From “Auditory Phenotype and Karyotype of 200 Women with Turner 






















 Fifty-five patients (26 males, 29 females) with NPC, confirmed via biochemical 
or molecular markers, were enrolled in this study between 8/14/2006 and 12/27/2010.  
Five sibling pairs, including one set of monozygotic twins, are included in the cohort.  
The mean age at enrollment was 11.6 years (SD =10.2 years), although there is large 
variability in age (minimum = 4 months, maximum = 51.3 years), as shown in Figure 1.  
Just over half (53%) of the cohort was less than 10 years of age, and the majority (80%) 
fall within a pediatric range of less than18 years. The average age of disease onset was 
3.7 years (Figure 2) and, while the initial symptom most often involved the hepatic 
system, 16 individuals presented with early neurological findings (Table II). 
 Thirty-five (64%) patients were able to participate to some degree for behavioral 
testing, which resulted in data that varied from a single pure-tone threshold to a complete 
audiological evaluation.  Alternatively, 20 patients were unable to provide any behavioral 
data, which was a reflection not only of a patient’s age, but also disease status.  Among 
these 20 cases, the age range varied from six months to 32 years.   
 Within the cohort of 55, five patients presented with a late-onset variant of the 
disease; these five patients ranged in age from 25 to 46 years in age at the time of their 
diagnosis.  In addition to this atypical disease onset, these patients each presented with 
unique auditory histories and findings.  Therefore, their data have been removed from the 








Figure 1. Age at enrollment of study for 55 patients with NPC.   
 
 





Table II. Presenting symptom, determined via oral histories and medical records provided 
to Dr. Forbes Porter. 
Presenting Symptom (n) 
Hepatic dysfunction / Jaundice (19) 
Splenomegaly  (17) 
Learning delay (5) 
Fetal ascites (3) 
Clumsiness / Poor coordination (3) 
Developmental delay (2) 
Cognitive decline/ Slurred speech (1) 
Depression (1) 
Fine motor ataxia (1) 
Hearing loss (1) 
















Baseline audiometry findings.  Mean (SD) pure-tone air-conduction thresholds at 
baseline for 31 patients (late-onset cases removed) ranging in age from three to 21 years 
(x‾  =10.9, SD=5.6) are plotted in Figure 3, and reveal an average high-frequency hearing 
loss phenotype across the cohort. There are no obvious asymmetries between right and 
left ears.  Mean data are closer to the cutoff for normal/abnormal than to the reference 
value for normal hearing (0 dB HL).  
Because this is predominantly a pediatric population, the normative cut-off for 
hearing loss in an adult (Table 1) was modified to a normative cut-off of 15 dB HL that is 
more appropriately applied to children (Clark, 1981).  When sufficient pure-tone data 
were collected to determine degree of hearing loss (.5/1/2/4 kHz PTA), 13 of 52 (25%) 
ears had a mild loss; the remaining ears (75%) were categorized as within normal limits.  
When percent of ears with hearing loss (>15 dB HL) by frequency is evaluated (Figure 
4), approximately half of the sample exhibited hearing loss involving the high 
frequencies.  When a high frequency average (.4/8 kHz) is considered (Table III), the 
degree of hearing loss ranged from within normal limits to a moderate loss.  
Bone conduction data were obtained in fewer cases than air-conduction (Table 
III) because of patient fatigue and lack of cooperation.  When bone conduction data 
(.5/1/2 kHz PTA) are not available, type of hearing loss cannot be determined. Thirty-one 
of 62 ears with pure-tone data had insufficient bone conduction data to determine type of 
hearing loss (.5/1/2 kHz PTA).  Of the remaining 31 ears, 26 had no hearing loss (as 
operationally defined in Table I), two had conductive, and three had sensorineural 




baseline evaluations: 15 by behavioral evaluations of hearing and 10 via sedated 

















Figure 3. Mean (SD) pure-tone air-conduction thresholds for 31 patients ranging in age 
from 3 to 21 years (x‾  =10.9; SD=5.6). 
 
 






Table III. Pure-tone averages for air- and bone-conduction data from 31 patients with NPC. 














Mean 13.1 10 14.9 12.2 14.1 9.5 20.7 
SD 6.6 6.5 8.1 8.1 5.1 5.2 15.8 
Range 1.7 - 28.3 -1.7 – 26.7 2.5 – 37.5 0 – 35 5 – 22.5 0 – 20 0 – 60 
 




A mixed model linear regression analysis failed to reveal any relationships 
between hearing and the independent variables age (baseline, disease onset, time from 
disease onset), gender, or use of miglustat (Table IV).  Mean (SD) thresholds by pure-
tone averages are plotted for gender in Figure 5. At baseline, 12 patients tested positive 
for miglustat, 16 tested negative, and three samples were unavailable.  Scattergrams by 
age showing the spread of distribution between miglustat groups are plotted for mid-
frequency (.5/1/2/4 kHz) and high-frequency (4/8 kHz) pure-tone averages in Figure 6.  
The relationship between age at disease onset and these pure-tone averages at baseline is 
shown in Figure 7.  Cross-sectional data showing the distribution of hearing (mid- and 
high-frequency pure-tone averages) by age at baseline are shown in Figure 8.  There are 
no obvious associations between these variables associated with age and hearing.  
Suprathreshold speech findings.  Maximum suprathreshold speech recognition 
performance in quiet for 35 patients able to participate in testing is plotted in Figure 9.  
Overall, performance was consistent with peripheral hearing sensitivity.  A rollover index 
(RI) was calculated for the 20 patients who could participate in monitored live voice NU-
6 word testing at two levels (moderate and high dB SL re: SRT).  The RI was considered 
significant if it was greater than 0.25 (Bess, et al.,1979)   Five patients exhibited 
significant decline in their performance (rollover) when speech was presented at the 
higher intensity level; one patient has a late-onset variant of the disease, and the other 
four fall within the pediatric classical onset.  In all cases, this finding supports 
retrocochlear dysfunction of the auditory system; however it should be noted that stimuli 






Table IV. Results of mixed model linear regression analysis of hearing for included 
predictor variables. 
Dependent 
Variable Predictors     





.5/1/2 kHz      
 Miglustat 4.20 2.53 1.662 .111 




.253 .228 1.110 .278 




-.318 .331 -.961 .348 
.5/1/2/4 kHz      
 Miglustat 4.84 3.11 1.557 .134 




.366 .281 1.305 .204 




-.241 .432 -.558 .583 
4/8 kHz      
 Miglustat 6.67 6.56 1.017 .321 




.700 .585 1.197 .243 




-.193 .891 -.216 .831 
 
Note.   B coefficient estimates variation in hearing accounted for by the predictor, and the 






Figure 5. Mean (SD) PTA air-conduction thresholds for male and female participants.  
















Figure 6.  Hearing thresholds for a four-frequency (top panel) and high-frequency 
(bottom panel) PTA.  Filled circles represent ears from 12 patients who tested positive for 
miglustat at baseline.  Open triangles represent ears from 16 patients with no evidence of 








Figure 7. Hearing thresholds (ears) for a four-frequency (top panel) and high-frequency 
(bottom panel) PTA at baseline by the age of disease onset (based on patient report and 








Figure 8. Hearing thresholds (ears) at baseline for both a four-frequency (top panel) and 










Figure 9. Maximum suprathreshold speech recognition performance in quiet by three-
frequency PTA for 70 ears with NPC.  NU-6, Northwestern University Test #6; PBK, 














Immittance findings.  Immittance data were collected on 54 patients.  Table V 
shows the percentage of normal and abnormal findings for tympanometry and the 
acoustic reflex.  Overall, middle ear status fell within normal limits for tympanometry.  
The most common abnormality observed was TPP, which revealed both positive and 
negative pressure findings.    
Acoustic reflex thresholds were abnormal (elevated or absent) in 92% of patients 
in whom these data could be collected.  Sixty-three percent of these cases cannot be 
explained by either middle ear status or peripheral hearing thresholds.  Although acoustic 
reflex adaptation could only be evaluated in a small number of individuals (n=10), 
adaptation was abnormal (positive) in four (40%) of these cases.  Both the acoustic reflex 
threshold and adaptation findings suggest retrocochlear dysfunction of the auditory 
system for a significant percentage of the cohort in whom these data could be collected. 
Otoacoustic emissions findings.  DPOAEs were measured in all 55 patients (110 
ears).  In cases with significant middle ear dysfunction (i.e., outside the age-appropriate 
normative range for tympanometry), OAE data were removed from analysis.  Late-onset 
cases are analyzed separately.   Mean (SD) DPOAE level data from the remaining 82 ears 
are plotted in Figure 10.  The large variability in DPOAE level is not surprising in such a 
heterogeneous population.  Analysis of present versus absent DPOAEs by frequency 
across the cohort (Figure 11) revealed over half of ears had absent low frequency 
DPOAEs (842 Hz – 1000 Hz), because of an elevated noise floor (Figure 9).  DPOAEs 
were present in 50% to 75% of ears at frequencies from 1189 Hz to 6727 Hz, with only 





Nonlinear TEOAEs were collected on 19 individuals in an attempt to test for 
TEOAE suppression.  Of those 19, eight individuals had present nonlinear TEOAEs and 
were able to continue participation to measure for suppression.  Seven of these 
individuals had measureable TEOAE suppression (≥ 1 dB) in their overall response; one 

























Note. WNL, within normal limits; CNT, could not test; Vec, equivalent ear canal volume; TPP, tympanometric peak 
pressure.  *Includes four ears with intact, patent pressure equalization tubes  **63% (15/24) cannot be explained by 
middle ear status or peripheral hearing thresholds.




 WNL Abnormal CNT 
  High Low  
Vec (cm3) 79% (85) 18% (19)* 3% (4)  
Admittance (mmhos) 82% (88) 9% (10) 9% (10)  
  Negative Positive  
TPP (daPa) 53% (57) 17% (18) 24% (26) 6% (7)* 
     
Acoustic Reflex Findings 
(n=26 patients) 
 WNL Abnormal CNT 
Acoustic Reflex Thresholds 8% (2) 92% (24)**  





Figure 10. Mean (SD) DPOAE amplitude and noise floor from 82 ears with no significant 
middle ear disease (late-onset cases removed). 
 
 
Figure 11.  Percent of ears without significant middle ear disease (late-onset cases 




ABR findings.  Baseline neuro-otologic ABRs were collected in 54 patients (107 
ears).  Table VI shows the number of ears (without late-onset cases, n=97 ears) with 
normal and abnormal findings for both absolute and interpeak latencies.  Results reflect 
averaged (condensation and rarefaction) responses to ipsilateral stimulation of each ear.  
The most common ABR abnormalities observed were poor waveform morphology, 
characterized by absent waves I and III, and prolongation of the interpeak interval 
between waves I-III and I-V.  Forty-one of 49 patients (84%) had an ABR abnormality in 
at least one ear.  Of these, nine had normal hearing and abnormal ABR results; 11 had 
peripheral hearing loss, but ABR abnormalities were disproportionate to the degree of 
loss (e.g., mild high frequency hearing loss, present wave I, absent wave III); three 
patients had hearing loss that could account for the ABR abnormalities; and 18 patients 
had no behavioral peripheral hearing data with which to compare to their ABR 
abnormalities. 
An additional salient finding on ABRs collected in this cohort were large and 
prolonged sinusoidal activity occurring in the first few milliseconds (e.g., 1-5 ms) of the 
recording, interpreted as cochlear microphonic (CM).  Figure 12 shows ABRs collected 
using the same equipment and under the same paradigm from a 45-year-old female 
without NPC, and without neurological disease.  Both the right and left ABRs are normal 
and the CM observed in the left ear is an appropriate duration (< 1 ms).  There is no CM 
observed in the right ear.  Because the ABR is not the ideal measurement to record the 
CM, its absence on the ABR is not considered a pathological finding.   
Figure 13 shows the ABR traces from a six-year-old male with NPC.  Large 




Specifically, the CM in the left ear extends out to approximately 4 ms and the CM in the 
right ear extends out to just beyond 3 ms.  Quantification of these responses is difficult; 
latency is the most efficient and accurate way to interpret data, and there are no 
normative criteria for CMs observed on the ABR.  Based on the observation of hundreds 
of ABRs collected on the same equipment using the same test paradigm, a criterion of     
> 1 ms was established as an abnormal finding.  Of 89 ears in which a CM was visible 
during the ABR recording, 34 (44%) showed evidence of prolonged responses.  Many of 
theses responses were noted to be large in amplitude as well (e.g., Figure 13).  These are 
interpreted as CM activity because the responses reversed polarity when the stimulus 
polarity was reversed.  Neural responses do not reverse polarity with changes in stimulus 
polarity.  Electrical artifact was ruled out via a control run when the same stimulus was 
delivered and the tubing of the insert earphone was clamped; in such cases activity 
interpreted as CM was not present. 
Site of lesion.  When each patient’s collective findings are considered, an 
individual profile of a cochlear, retrocochlear, or mixed site of lesion is available for 40 
patients.  The remaining 15 patients lacked sufficient data to determine a site of lesion. 
Results of this analysis are shown in Table VII.  Pure cochlear hearing loss (e.g., elevated 
pure-tone thresholds, absent DPOAEs, normal acoustic reflexes, normal ABR) was 
observed in 7% of patients.  Retrocochlear dysfunction of the auditory system alone (e.g., 
pure-tone thresholds within normal limits, present DPOAEs, elevated/absent acoustic 
reflexes, abnormal ABR) occurred in 35% of patients.  The most common single finding 




Retrocochlear dysfunction with or without evidence of cochlear involvement occurred in 









Table VI. Absolute and interpeak latency data for ABRs collected on 49 patients (late-onset cases removed). 
 Absolute Latencies Interpeak Latencies 
 I III V I-III III-V I-V 
Normal 
latencies 
59% (57) 57% (55) 76% (74) 45% (24) 85% (63) 62% (36) 
Prolonged 
Latencies 
1% (1) 18% (18) 18% (17) 55% (29) 15% (11) 38% (22) 
Absent Waves 40% (39) 25% (24) 6% (6) * * * 
 






Figure 12. ABRs from a 45-year-old female without NPC or neurological disease, 
collected using the same equipment under the same test paradigm described in this study. 
ABRs are interpreted as normal, and the CM observed (circled area) following 
stimulation of the left ear (top panel) is considered appropriate in amplitude and duration.  





Figure 13. ABRs from a six-year-old male with NPC.  Large amplitude and prolonged 







Table VII. Percentage of cases (n=40) that are classified as either normal or abnormal 
for cochlear and retrocochlear dysfunction, and those cases (shaded area) that qualify as 














Longitudinal Data.  Longitudinal data are available for 30 patients.  The duration 
of follow-up is plotted in Figure 14 for 18 patients with longitudinal pure-tone data (top 
panel) and 26 patients with longitudinal ABR data (bottom panel) (late onset cases 
removed).  The majority of patients in both subsets were followed for two or more years.  
Age and change in disease status resulted in patients able to participate reliably in some 
testing at baseline who were then unable to provide the same data at return visits, or vice 
versa.  Because of this limitation, and the variability in the duration of follow-up, 
rigorous statistical analysis on any of the longitudinal data is not possible.  Descriptive 
results are presented below. 
Pure-tone findings:  Longitudinal pure-tone data for a four-frequency and high-
frequency pure-tone average, and for 8k Hz are plotted in Figure 15.  Patients followed 
longitudinally ranged in age from four to 21 years at the time of their final follow-up 
audiogram.  Hearing sensitivity in several ears is noted to improve (- change in hearing) 
from baseline, although most of these changes are not outside of test-retest variability (+/- 
10 dB).  No significant change in averaged mid-frequency (.5/1/2/4 kHz) hearing is 
noted; of 30 ears with data, only one had a clinically significant (>10 dB) decline in 
hearing of 12.5 dB.  However, the high-frequency average reveals several ears that had 
significant decline in hearing sensitivity from baseline.  Of 12 ears followed for 23 
months or more, nine (75%) had a clinically significant (>10 dB) decline in hearing.  The 
largest change in hearing for the high-frequency average (32.5 dB and 27.5 dB for the 
right and left ears, respectively) occurred in the individual followed for the longest period 
of time (135 months); she was 21 years at the time of her final audiogram.  The trend of 




viewed; eight of 12 ears (66%) showed clinically significant decline in hearing, with an 
average change of 29 dB.  For individuals followed for less than a total of 23 months, 
only one ear at 2000 and 4000 Hz had a significant decline in hearing (15 and 20 dB, 
respectively). Of the 10 patients followed for at least a two-year period, who ranged in 
age from 6 to 21 years, eight have had clinically significant declines in hearing; the 

























Figure 14. Duration of follow-up for 18 patients with longitudinal pure-tone data (top 





Figure 15. Change in hearing from baseline against duration of follow-up (months) for a 




 ABR findings: Twenty-six patients provided longitudinal ABR data, with an 
average duration of follow-up of 18 months.  Clinically significant change (> 1 ms, e.g., 
Hood, 1998, Ornitz & Walter, 1975) from baseline was not observed in either ear of any 
individual for absolute latency (I, III, V) or interpeak latency (I-III, III-V, I-V).  Change 
from baseline for these measures is plotted in Figures 16 and 17.  A positive change 
indicates a prolongation in latency, and a negative change indicates a reduction in 
latency.  There is no observable trend in the data, in either direction, to suggest an overall 
pattern of change in the cohort.  However, there appears to be more stability in the 
response for the absolute latency of waves I and III, and a less stable response (both 
positive and negative change) for the absolute latency of wave V.  A similar pattern was 
not observed on the interpeak latency data.  ABR waves undergoing a categorical change 
from present to absent are not included in these figures.  
 Table VIII shows the number of ears from 12 individuals with longitudinal ABR 
data that underwent a categorical change from present to absent or normal to abnormal 
during the duration of follow-up.  The most common finding was a loss (present to 
absent) of waves I and III.   
OAE Suppression findings: Of the 8 individuals for whom OAE suppression 
could be tested; three provided longitudinal data.  Two of the three individuals were 
followed for three years and had OAE suppression present in at least one ear on two 
occasions.  The third patient was followed for one year, had measurable suppression at 
baseline bilaterally, and no measurable suppression in either ear on her follow-up visit.  




neither of these girls showed evidence of a prolonged CM on their ABR.  The third 
patient who lost suppression had a large CM in both ears on both visits.  
This relationship between a prolonged CM and presence/absence of OAE 
suppression was explored because it is speculated that large and prolonged CMs may 
represent a lack of regulation by the olivocochlear efferent system on cochlear hair cell 
activity (Starr, Sininger, & Pratt, 2000).  If OAE suppression functions as a non-invasive 
window into auditory efferent pathways, such as the olivocochlear efferent system, that 






Figure 16. Change in ABR absolute latency from baseline by duration of follow-up 






Figure 17. Change in ABR interpeak latency from baseline by duration of follow-up 




Table VIII. Categorical change in absolute and interpeak ABR latency findings from 26 





















Longitudinal ABR Change 
Present to Absent (ears) 
I III V 
7 3 0 
Normal to Abnormal (ears) 
I III V 
0 2 3 
I-III III-V I-V 




Longitudinal Case Examples.  Four longitudinal case examples are provided from 
individuals who were able to provide complete audiological evaluations at multiple 
points in time (Figures 18 through 22).  Case one (Figure 18) shows threshold data from a 
male patient with NPC at six and eight years of age.  At the baseline visit, he presented 
with a slight low-frequency conductive hearing loss secondary to Eustachian tube 
dysfunction.  On his return visit at eight years of age, middle ear function and the low-
frequency component resolved, however there was a new-onset precipitous decline in 
high-frequency hearing.  Case two (Figure 19) shows threshold data from a male patient 
with NPC at seven and nine years of age. A significant decline in hearing was 
documented from 2k to 8k Hz bilaterally, although there was no patient or parental 
concern regarding a change in hearing and no concomitant change in middle ear function.  
Case three (Figure 20) shows threshold data from a male patient with NPC at seven and 
11 years of age. When the patient presented at baseline, there were no parental or patient 
concerns regarding hearing sensitivity.  At that time, a moderate high-frequency hearing 
loss was newly identified.  Following identification of hearing loss at baseline, this 
patient was subsequently fit with bilateral hearing aids.  At follow-up, a significant 
decline in hearing was documented at most test frequencies between 2k and 8k Hz, 
although there was no concern regarding a change in hearing, and no significant change 
in middle ear status was documented.  
Case four (Figure 21) shows threshold data from a female patient with NPC at 
nine and 21 years of age (historical records available).  A progressive decline in high 
frequency hearing was documented across multiple interim evaluations and a similar 




the longest duration of follow-up in this cohort.  The corresponding ABR data for this 
patient are shown in Figure 22.  ABRs obtained in 1995 compared to those obtained in 
2006 reveal a loss of waves I and III in the left ear and a total loss of the response in the 


























Figure 18. Right ear pure-tone air-conduction thresholds for a male patient with NPC at 
















Figure 19.  Right ear pure-tone air-conduction thresholds for a male patient with NPC at 
















Figure 20.  Left ear pure-tone air-conduction thresholds for a male patient with NPC at 















Figure 21.  Right ear pure-tone air-conduction thresholds for a female patient with NPC 







Figure 22. ABR results are from the patient described in longitudinal case 4, and 
correspond to pure-tone thresholds shown in Figure 21.  Right ear responses are shown in 













Late-onset cases.  Five patients presented with late-onset stages of NPC.  Each 
presented with unique medical and auditory histories, and as such, each will be presented 
below as a case example.  An audiogram key is provided in Appendix B. Table IX 
summarizes findings from the five late-onset cases of NPC in this cohort.  All five 
patients have hearing loss, although two of the five were unaware of their loss at the time 






















 This is a 25-year-old female with NPC.  She was diagnosed with 
hepatosplenomegaly at five years of age and bilateral hearing loss during middle school.  
Additional neurological decline during early adulthood ultimately led to the diagnosis of 
NPC several months prior to her NIH baseline evaluation (Figure 23).  She has normal 
tympanometry and absent ipsilateral and contralateral acoustic reflexes bilaterally.  
Otoacoustic emissions are absent bilaterally.  The ABR is absent in the left ear and only 
wave V is present in the right ear, which is consistent with the degree of peripheral 
hearing loss. 
 
Figure 23.  Baseline NIH audiogram for a 25 year old female with NPC.  Low-frequency 







This is a 32-year-old male with NPC.  The patient was diagnosed with a learning 
delay at age 8, and “idiopathic” high frequency hearing loss at age 9.  He was diagnosed 
with NPC at 21 years of age after significant and rapid neurological decline.  At his 
baseline NIH evaluation he had normal middle ear function and absent otoacoustic 
emissions bilaterally.  He was unable to cooperate for acoustic reflex or behavioral 
hearing assessment.  His ABR, obtained under sedation, was absent bilaterally.  
Historical audiograms indicate a significant deterioration in hearing up to age 18.  Figure 
24 is the most recent, complete audiogram for this patient, who is now 32 years old and 
unable to condition for behavioral evaluations. 
 
Figure 24. Audiogram for a male patient with late-onset NPC.  Historical audiograms 
from the age of  nine to 18 years, when the above audiogram was obtained, show a 





This is a 33-year-old female with NPC.  She was initially diagnosed with 
schizophrenia at age 18; she later developed vertical gaze palsy, decreased motor skills, 
and difficulty ambulating.  She was diagnosed with NPC at the age of 33 years.  She 
presented to her baseline NIH evaluation, accompanied by her mother, with no concern 
regarding her hearing.  Middle ear function was normal, but acoustic reflexes were 
elevated bilaterally, inconsistent with the degree of peripheral hearing loss.  DPOAEs 
were consistent with behavioral pure-tone hearing thresholds (absent in the high 
frequencies).  Waves I and III of the ABR were absent bilaterally and wave V was 
present at a normal absolute latency, which suggests a cochlear contribution to the poor 
ABR morphology.   
 
Figure 25. Baseline NIH audiogram from a 33-year-old female with NPC.  Neither the 




Case 4.  
This is a 35-year-old female with NPC.  She was initially diagnosed with 
depression at age 18.  Following the onset of progressive neurological involvement 
beginning around age 30, she was ultimately diagnosed with NPC at age 34.  Neither she 
nor her mother had concern about her hearing prior to her baseline NIH evaluation 
(Figure 26).  She presented with normal middle ear function and elevated/absent acoustic 
reflexes that were incongruous with pure-tone hearing thresholds, and positive 
(abnormal) acoustic reflex adaptation.  DPOAEs were consistent with behavioral 
thresholds (high frequency hearing loss).  Wave I of the ABR was absent bilaterally, but 
otherwise the ABR was within normal limits, which is consistent with a high frequency 
hearing loss of a cochlear origin.  
 
Figure 26. Baseline NIH audiogram from a 35-year-old female with NPC.  Neither the 





This is a 51-year-old female with NPC.  She was diagnosed with bilateral hearing 
loss at the age of 39.  One year later she presented with slurred speech, ataxia, and 
difficulty swallowing; three years later she developed significant motor impairment.  She 
was diagnosed with NPC at the age of 46.  She is unaware of any change in hearing since 
the hearing loss was initially diagnosed.  Audiological testing revealed normal middle ear 
function with absent ipsilateral and contralateral acoustic reflexes (.5/1/2 kHz), which 
was incongruous with low-frequency peripheral hearing thresholds.  Suprathreshold word 
recognition testing revealed significant decline in performance (80% to 52%) in the right 
ear.  DPOAEs were absent bilaterally.  ABRs were absent bilaterally, which could not be 
explained entirely by peripheral hearing thresholds.   
 
Figure 27. Baseline NIH audiogram for a 51-year-old female with NPC.  The patient was 
















*Female 25 25 Y Dx with hepatosplenomegaly at age 5; Dx with 
bilateral HL in middle school 
*Male 32 21 Y Dx with learning delay at age 8; Dx with 
bilateral HF HL at age 9 
 Female 33 33 Y Dx with schizophrenia at age 18; later 
developed vertical gaze palsy, decreased motor 
skills, and difficulty ambulating; no concern 
about hearing 
 Female 35 34 Y Dx with depression at age 18; onset of 
progressive neurological involvement beginning 
around age 30; no concern about hearing 
*Female 51 46 Y Dx with bilateral HL at age 39; 1 year later 
presented with slurred speech, ataxia, and 
difficulty swallowing; 3 years later, significant 
motor impairment 
 
Note. Dx, diagnosed; HF, high frequency; HL, hearing loss. * identifies three of five 





Summary and Discussion 
The data presented here represent the largest cohort of patients with NPC in 
whom auditory function has been examined comprehensively.  Results of the baseline 
auditory assessment support an auditory phenotype in humans with NPC.  When mean 
data (Figure 3) for the cohort of 31 patients (late-onset cases removed) able to participate 
in behavioral testing are viewed, a high frequency hearing loss is evident.  Insert 
earphones were used as the standard for data collection whenever possible, which 
mitigates the risk that findings represent an artifact from standing waves or collapsing 
external auditory canals.  These findings corroborate previous reports from a small cohort 
of patients with NPC with high frequency hearing loss (Fink, et al., 1989; Pikus, 1991).  
When a four-frequency pure-tone average is used to quantify hearing loss in this 
cohort, only 25% of ears are identified as having a hearing loss; however, approximately 
half of all ears had clinically significant hearing loss (>15 dB HL) at 4000 and 8000Hz.  
This observation suggests that standard mid-frequency pure-tone averages may be 
inadequate to capture accurately hearing loss in patients with NPC.  Furthermore, early-
onset hearing loss in this population may be missed easily, as common screening 
procedures for hearing in medical offices and academic settings typically do not test 
above 4000 Hz (e.g., McPherson, Law & Wong, 2010).  Efforts during behavioral 
evaluations in this difficult-to-test population should emphasize collection of high 
frequency information first, when possible, with the knowledge that a complete 
behavioral exam may not be feasible. 
The majority of hearing loss observed in this cohort with NPC appears to be 




obtain and are, consequently, limited, middle ear disease was not a prevalent finding in 
this group.  The most common abnormality observed was on measures of TPP, which is a 
reflection of Eustachian tube dysfunction, and which is not uncommon in a pediatric 
population.  Children are more susceptible to middle ear disease, in part, because of the 
horizontal positioning of their Eustachian tube, which regulates pressure in the middle ear 
cavity.  An additional factor for consideration when interpreting middle ear function is 
that many participants travel to the NIH via commercial aircraft and are typically seen 
one to two days after arrival; residual effects from flight on middle ear status can occur, 
and may actually be greater in children (Mirza & Richardson, 2005).  Previous reports 
from a single cohort (e.g., Fink, et al., 1989; Pikus, 1991) did not observe abnormal 
tympanometry findings, but normative criteria used for categorization were not specified.  
Middle ear disease is a concern for any pediatric population, and as a noninvasive, 
relatively quick assessment of middle ear status, tympanometry should play an important 
role in identifying possible conductive pathology in this population in whom collection of 
ear-specific bone-conduction pure-tone thresholds can be difficult. 
In the current study, otoacoustic emission data support a cochlear site of lesion 
(sensory), specifically the outer hair cells, in ears with absent OAEs, when cases of 
middle ear dysfunction are removed.  When low-frequency emissions (≤ 1000 Hz) are 
discounted because of an elevated noise floor, DPOAE data suggest cochlear dysfunction 
in approximately one third of all participant ears tested; the most common range affected 
was the high frequency range, which corresponds with the high frequency pure-tone 
hearing loss observed in this group.  While this is the first time OAE data have been 




thresholds in all cases.  That is, ears with hearing loss had appropriately absent OAEs at 
frequencies corresponding to the hearing loss.  This supports cochlear dysfunction as part 
of the auditory phenotype.  OAEs can serve as an especially useful tool to either screen 
for peripheral hearing loss or help confirm behavioral thresholds in a young, 
neurologically compromised population, and should be included in every auditory 
assessment of patients with NPC.  
In addition to evidence for a cochlear site of lesion in NPC, there is support for 
retrocochlear dysfunction of the auditory system in a large percentage of the cases.  
Twenty-five percent of patients who were able to provide word recognition responses at 
two presentation levels showed evidence of rollover in performance, suggesting 
retrocochlear involvement.  Word recognition scores from ears with purely cochlear 
hearing loss tend to plateau or exhibit a slight decline in performance with an increased 
presentation level.  Patients with retrocochlear dysfunction, however, tend to exhibit a 
dramatic decline in performance with increases in intensity beyond the level required to 
obtain their maximum performance (Jerger & Jerger, 1971).   
Similarly, 63% of ears had abnormal acoustic reflex patterns that could not be 
explained by either middle ear status or peripheral hearing thresholds, suggesting 
retrocochlear involvement.  Retrocochlear disorders are suspected in ears where the 
acoustic reflex threshold is either elevated or absent beyond what would be anticipated by 
cochlear hearing loss, and in the absence of middle ear disease.  In addition, acoustic 
reflex adaptation, which was abnormal in 15% of cases, is also consistent with a 
retrocochlear site of lesion.  These data are consistent with those from Fink, et al. (1989) 




adaptation abnormalities (81% and 85%, respectively).  When middle ear status and 
peripheral hearing are accounted for, an abnormal acoustic reflex indicates a disturbance 
in the reflex arc comprising cranial nerves VII and VIII, the cochlear nuclei, and the 
superior olivary complex.   Additional support for a neural site of lesion is found in the 
ABR results.        
ABR abnormalities were observed in 84% of patients, of whom 49% had 
abnormalities that could not be explained by peripheral hearing status; an additional 44% 
had no peripheral hearing data with which to compare results.  The most common 
findings were absent waves I and III and prolongation of interpeak latencies I-III and I-V  
While absence of early waves can be attributed to high frequency peripheral hearing loss, 
prolongation in interpeak latencies indicates a disturbance in transmission of the auditory 
nerve through the lower brainstem.  Although specific ABR abnormalities in previous 
reports are limited, current data are not inconsistent with earlier findings that implicate a 
disturbance in the early components of the ABR waveform (Aisen, et al., 1985; Fink, et 
al., 1989; Palmeri, et al., 2005; Pikus, 1991) and suggest auditory nerve and auditory 
brainstem dysfunction. 
A pattern of disproportionate neural findings that cannot be explained by degree 
of peripheral hearing loss implies that some patients with NPC fit the diagnostic criteria 
for auditory neuropathy spectrum disorder (ANSD).  ANSD is a disorder of afferent 
transmission from the cochlea through the auditory nerve, believed to disrupt the 
temporal processing of a signal.  The original description of the disorder involved 
elevated pure-tone thresholds, disproportionately poor speech discrimination abilities, 




peripheral hearing loss (Starr, Picton, Sininger, Hood, & Berlin, 1996).  It is now widely 
accepted that ANSD encompasses a continuum of clinical findings and a wide range of 
etiologies (e.g., syndromic and nonsyndromic, neonatal hyperbilirubinemia, idiopathic) 
resulting in a depletion or dyssynchrony of afferent auditory nerve fibers, or both (Picton, 
2011).     
Today, the diagnostic criteria for ANSD include evidence of cochlear hair cell 
function (OAEs and/or cochlear microphonic) and abnormal processing of the auditory 
nerve, usually established through ABR abnormalities beginning with the early 
components (e.g., wave I) of the waveform (Picton, 2011).  Additional useful tests 
include acoustic reflex thresholds and adaptation (Berlin, et al., 2005) and OAE 
suppression via a contralateral masker (Hood, Berlin, Bordelon, & Rose, 2003), both of 
which are reported to be abnormal in ANSD.  Some children with ANSD exhibit large 
amplitude and prolonged latency CMs (Starr, et al., 2000; Starr, Sininger, Nguyen,  
Michalewski, Oba, Abdala, 2001). 
Based on the above diagnostic criteria, 12 patients in the NPC cohort have 
audiometric findings consistent with ANSD.  These 12 individuals have both intact 
cochlear function and abnormal ABR findings that begin in the early part of the 
waveform and that cannot be explained by peripheral hearing status.  This number may 
be an underestimation of the prevalence of ANSD in NPC disease because 15 patients 
were unable to provide enough data to determine their inclusion or exclusion from this 
category.   
A large number of participants (40%) exhibited a mixed, cochlear and 




participant with elevated pure-tone thresholds, absent otoacoustic emissions (cochlear), 
elevated/absent acoustic reflex thresholds and/or abnormal ABR findings that could not 
be explained by the degree of peripheral hearing loss.  This high proportion of patients 
with retrocochlear and cochlear involvement further lends support for NPC disease 
pathogenesis having a widespread and complex role within the auditory system.   
Thirty-six percent (20/55) of the cohort who ranged in age from four months to 32 
years were unable to provide any behavioral pure-tone data during examination, 
suggesting that, in addition to young age, disease status can be a significant barrier to 
obtaining a complete audiological evaluation in patients with NPC. In those patients for 
whom no behavioral data could be obtained, Auditory Steady State Response (ASSR) 
measures were used to estimate peripheral hearing sensitivity for the purpose of 
determining appropriate clinical intervention while the patient was sedated.  These data 
were not included in the statistical analysis aimed at phenotyping NPC because of the 
variability associated with these predictions of behavioral thresholds (Yeung & Wong, 
2007).  ASSR thresholds have been shown to overestimate hearing loss in normal hearing 
ears and in ears with ANSD (Attias, Buller, Rubel, & Raveh, 2006).  Nevertheless, 
ASSR, in conjunction with tympanometry and OAEs, was the only assessment option in 
about one-third of the cohort.  Taken together, auditory evoked potentials and behavioral 
auditory testing identified hearing loss in 23 patients (42%) with NPC. When all patients 
with at least a mild sensorineural hearing loss are considered (32) this means that 72% of 
these participants were unaware of their hearing loss.  This, in part, supports the 
hypothesis that hearing loss is an overlooked, underestimated component of the NPC 




The tremendous heterogeneity and relatively small size of the sample made 
identifying contributions of specific independent variables to observed hearing loss 
challenging.  Only eight patients (15%) were able to participate in every component of 
the test battery.  This limited number essentially precluded a meaningful mixed model 
regression analysis with multiple variables.  Although gender, age, and miglustat were 
not identified in the current study as contributing to the variability in hearing sensitivity 
among the current NPC patients, definitive findings await a larger sample size (minimally 
five to ten participants per predictor variable).   
There is evidence of progressive hearing loss accompanying NPC.  This is 
supported by the subset of longitudinal data identifying clinically significant (>10 dB) 
change in high frequency hearing.  Of 12 ears followed for 23 months or more, 75% 
experienced decline in hearing, and the ears that experienced the largest deterioration 
(>27 dB) were those followed for the longest period of time (~11 years).  In addition, the 
four longitudinal case examples of patients who were able to provide multiple complete 
behavioral evaluations provide clear evidence of deterioration in hearing.  Although the 
heterogeneity and small size of the sample preclude observation of robust evidence for 
progression, these individual case examples and the subset of data from patients followed 
for the longest amount of time cannot be ignored.  Collectively, these data reveal for the 
first time that, like the global neurological phenotype, hearing in at least some patients 
with NPC is progressive.  This finding supports the importance of regular audiologic 
monitoring in all patients with NPC regardless of a history of normal hearing. 
Longitudinal ABR data fail to reveal any significant change (> 1 ms) in absolute 




underwent categorical change from normal to abnormal when compared to normative 
data.  The most common finding was a loss of waves I and III, and a prolongation in the 
I-III interval across an average duration of follow-up of 18 months.  These data suggest 
detrimental longitudinal change in ABR morphology is possible in patients with NPC, 
and Case 4 of the longitudinal examples provides clear evidence of a decline in waveform 
morphology for the patient followed for the longest duration (12 years).  It is possible that 
average duration of follow-up in the cohort (average 18 months) is not sufficiently long 
to view overt changes in ABR results across many patients.  Nonetheless, the ABR is an 
excellent tool for monitoring auditory neural status and should be considered for patients 
with NPC, especially those unable to participate fully in behavioral evaluations. 
Because of their unique disease progression and auditory findings, the data of five 
patients with late-onset NPC were removed from the overall cohort and analyzed 
separately.  These patients have more hearing loss than the cohort average, and in three of 
the five cases hearing loss was an early symptom of the disease; the remaining two 
patients were unaware of their hearing loss.  The only previous mention of hearing loss in 
late-onset cases of NPC was by Sévin et al. (2007), who identified three of 25 patients as 
having “perceptual deafness.”  Although the metric for hearing assessment was not 
identified, the authors reported that hearing loss was an early symptom of the disease in 
two of the three patients.  These two cases, in conjunction with the current findings, 
support hearing loss as a premonitory symptom in late-onset cases of NPC.  
Consequently, the inclusion of NPC should be added to the differential diagnosis for 
patients of any age with subtle neurological symptoms (e.g., learning delay) and 




While these data provide clear evidence for an auditory phenotype in humans with 
NPC, the pitfalls associated with longitudinal data collection in an outbred, 
heterogeneous, neurologically compromised pediatric population are evident, and prevent 
the rigorous application of statistics to much of the data.  Questions remain about the role 
of NPC mutations on auditory function, longitudinal progression of the neural phenotype, 
and the utility of the auditory system as a clinical marker for disease status and 
intervention efficacy.  With these in mind, experiment two focuses on exploring auditory 



















CHAPTER 3: AUDITORY FUNCTION IN THE MOUSE MODEL FOR 
NIEMANN-PICK DISEASE, TYPE C (NPC) 
Review of the Literature 
Mouse Models for Human Biology 
Overview.  In the last 100 years, the mouse has emerged as the most prominent, 
well-studied animal model for understanding mammalian, specifically human, biology 
(for review see Morse, 2007).  Its impressive status as an early leader among research 
models was evident in its selection to be the first organism targeted for complete genetic 
sequencing.  Within the last 10 years, both the human and mouse genomes were 
completely sequenced, providing an invaluable blueprint for understanding normal and 
aberrant genetic structure and function.  Today, mouse models exist for cancer, aging, 
immunology, metabolism, and inherited neurodegenerative diseases, among others.  It is 
the animal model of choice in many areas of research.   
Through the majority of the 20th century, genetic research with mice relied on the 
use of spontaneous, naturally occurring molecular mutations.  However, the ability to 
transfer genes and deoxyribonucleic acid (DNA) material across organisms (transgenesis) 
led to the discovery of gene ‘knockout’ technology, further enhancing the link between 
mammalian genetics and biology.  It is now also possible to replace an endogenous 
mouse gene with a new, exogenous molecular variant, using similar targeted insertion.  
With this gene knockout and knockin technology, it is possible to control the expression 
of a gene in a model organism - in this case, the mouse - to target its specific effect on 




Research with mice typically involves the use of inbred strains, whose lineage 
traces to a single ancestral pair, but who have been mated through their own siblings for 
at least 20 generations.  The outcome is a genetically uniform animal model.  Inbred 
strains of mice have led to remarkable discoveries in human heritability and biology, and 
are commonly used in research of the auditory system.  Consequently, a great deal is 
known about normal and aberrant auditory structure and function in the mouse, including 
similarities in inheritance patterns of auditory pathologies between mice and humans 
(Brown & Steel, 1994).  There are mouse models for outer and middle ear deformities, 
sensory hair cell defects, auditory CNS disorders, age-related hearing loss, and noise-
induced hearing loss, to name a few. 
The molecular and biological systems in this species are well understood and, in 
many ways, analogous to humans.  The anatomical and physiological features of the 
mouse and human cochleae are comparable in function (Johnson & Zheng, 2002) and 
there is approximately 95 percent sequence homology between the species (McFadden, 
Ding, & Salvi, 2001).  Moreover, they are characterized by a short lifespan (~18 to 24 
months), rapid reproduction cycle (18 to 21 day gestational period), malleable breeding, 
and inexpensive care.  For all of these reasons, the mouse model is ideal for 
understanding human biology and, in this case, auditory function or dysfunction.     
 Hearing in mice.  The mouse is a highly vocal animal, which suggests its ability 
to communicate and auditory sensitivity play an important role in social and behavioral 
function.  While some of these vocalizations occur at frequencies that are audible to 
humans, many are ultrasonic, upwards of 70 to 80 kHz (Nyby, 2001).  Most 




stimuli at these ultrasonic frequencies, which makes obtaining accurate auditory 
thresholds above 32 or 64 kHz difficult.  However, it is reasonable to assume these 
animals have not developed the capability to produce sounds that they themselves are 
unable to detect.  Considering the ultrasonic vocalizations that have been recorded from 
this species, it can be inferred that mice have high-frequency hearing that extends at least 
as high as 70 to 80 kHz.  According to the Greenwood function (Greenwood, 1990), and 
under the assumption that the mouse cochlea is 7mm long (Ehret, 1983), the upper 
frequency limit of hearing for the mouse could be as high as 120 kHz.      
The ability to determine both behavioral and electrophysiological auditory 
thresholds across an animal’s frequency response range has increased over recent decades 
with improved technology.  Heffner and Heffner (2007) published a review of 
audiograms for commonly used laboratory animals, including the mouse.  They 
compared the range of hearing across species for frequencies audible at a level of at least 
60 dB SPL.  In addition, they documented the range of frequencies for which each animal 
is most sensitive, defined as those audible at a level of < 10 dB SPL.  Based on these 
operational definitions, the range of hearing for humans extends from 31 Hz to 17.6 kHz, 
with the best sensitivity between .25 and 8.1 kHz.  In comparison, hearing in the 
domestic house mouse can range from 2.3 to 85.5 kHz, with a narrow range of sensitive 
hearing extending from 8 to 32 kHz, which is most sensitive at 16 kHz (Heffner & 
Masterton, 1980). 
There are multiple techniques available to test auditory function in the mouse.  
Using behavioral techniques, it is possible to evaluate absolute thresholds, frequency and 




(Heffner, Koay, & Heffner, 2001).  However, the conditioning procedures for such 
assessments can be difficult and require prolonged training periods before data collection 
can begin.  The acoustic startle reflex is another form of behavioral assessment, although 
even in alert and well-behaving animals the response is sensitive to environmental events 
in addition to effects from any underlying neurological or cognitive problems (Ison, 
2001).  In light of these issues, both the lifespan and the neurological integrity of the 
mouse must be considered before electing to conduct such behavioral procedures. 
The most popular method to assess hearing in mice is the use of physiological and 
electrophysiological measures, specifically the ABR and otoacoustic emissions (OAE).  
These are two noninvasive measures that require no training or conditioning of the 
animal and, as such, generate quick results that lend themselves to producing longitudinal 
data over a lifetime.  As with humans, OAEs and ABR alone in mice can only be used to 
infer information about auditory sensitivity, and provide no information about the 
animal’s ability to discriminate sounds.  Despite these limitations, the ABR, and more 
recently, distortion product OAEs (DPOAEs) have become the tools of choice for 
investigators studying auditory function in mice.   
The presence of OAEs is believed to reflect the active biological processes within 
the cochlea, specifically, the electromotile properties of the outer hair cells (e.g., Probst, 
Lonsbury-Martin, Martin, & Coats, 1987).  As observed in many species in which OAEs 
can be recorded, when outer hair cells are missing or severely damaged, such as in the 
case of significant hearing loss, emissions are absent.  Further evidence of this 
relationship exists in mouse models as well.  In the Bronx waltzer mouse, a mutant model 




are intact, clear and reliable 2f1-f2 emissions can be recorded (Horner, Lenoir, & Bock, 
1985).  However, Wv/Wv mutant mice that have defective cochlear outer hair cells but 
intact inner hair cells have absent DPOAEs (Schrott, Puel, & Rebillard, 1991).     
Most studies of OAEs in mice have used the same instrumentation and stimulus 
recording techniques as those used with humans.  This is, in part, due to a lack of 
research investigating effects of varying stimulus parameters on DPOAEs in mice, either 
in normal or impaired ears (Parham, Sun, & Kim, 2001).  As in humans, the largest 
distortion product consistently reported is the 2f1-f2, or the cubic difference tone.  Sun 
and colleagues (1997, 1998) offer one of the few investigations of DPOAEs with varying 
stimulus parameters in CBA/J and C57 mice, two commonly used strains in auditory 
research.  They conclude optimal stimulus parameters for assessing cochlear impairment 
in these mice are: f2/f1 = 1.35, L2= 20 to 30 dB SPL, and L1-L2 = 25 dB.  In general, 
across strains in normal mouse ears, it is accepted that the f2/f1 ratio resulting in the 
largest DPOAE level is near 1.2 when L1-L2 = 0 to 10 dB, but is > 1.25 when L1-L2 > 10 
dB (e.g., Parham, 1997).  Results can be less consistent when hearing loss is present 
(Parham et al., 2001), and therefore comparison of results across strains and with non-
littermates should be interpreted with caution. 
Currently, due to equipment limitations, the ability to measure DPOAEs in mice 
is restricted to primary frequencies below 20 kHz for most transducers. The detection 
threshold of the DPOAE is traditionally defined as the lowest primary level that produces 
an emission above the noise floor by a criterion amount (e.g., 3 or 6 dB).  Because little is 




interpreted commonly as either present or absent in order to infer the functional integrity 
of the cochlea.  
There are some distinct differences between DPOAEs recorded in humans and in 
mice.  Characteristics of the 2f1-f2 distortion product in the mouse are similar to other 
non-primate laboratory animals with respect to fine structure, input/output (I/O) 
functions, and effects of primary tone level and frequency separation (Parham, 1997).  
Typically, mice have higher level DPOAEs than humans, less pronounced fine structure, 
and fewer spontaneous and transient OAEs (Parham et al., 2001).  Consequently, 
DPOAEs should be compared carefully between species, with these differences in mind. 
The ABR in humans allows a gross estimation of the integrity of the auditory 
pathway up to and including the inferior colliculus, although far-field recording prohibits 
identification of specific nuclei or tracts as generation sites.  Early work in the area of 
auditory evoked potentials (AEPs) included a seminal study by Henry (1979) in which 
surgically induced lesion techniques and click-evoked ABRs were used to determine 
murine generation sites for this AEP.  He concluded that the first five positive peaks in 
the mouse ABR have the same generation sites as those that had previously been defined 
in the cat.  Specifically, P1 of the ABR in the mouse results from the contribution of both 
the summating potential (cochlear origin) and the compound action potential (firing of 
the auditory nerve).  The following four positive peaks, P2 through P5, correspond to the 
cochlear nucleus, the contralateral superior olivary complex, the lateral lemniscus, and 
the contralateral inferior colliculus, respectively. 
Various ABR characteristics have been used to quantify the response in mice.  




peak and interpeak latencies.  Threshold determination has been the most popular and 
well-studied approach to phenotyping auditory function in mice.  However, the ABR 
threshold will vary not only with the stimulus characteristics (e.g., click versus tone 
burst), but also with the age and the background strain of the mouse in question.  For 
example, both the BALB/cJ (Willott et al., 1998) and the C57BL (Henry, 1984) strains 
exhibit early-onset age-related hearing loss beginning as soon as postnatal day (p) 65.  
Obviously, normative ABR data for these mice will differ significantly from CBA mouse 
data, for example, in which age-related cochlear hair cell loss is not observed until eight 
months of age (Ding, McFadden, & Salvi, 2001).  For this reason, comparing ABR 
characteristics for the purposes of phenotyping mutant mice is best accomplished within 
littermates from the same colony and background strain.  In this case, results of affected 
mutants can be directly compared with their wildtype littermates who do not carry the 
mutation in question, but who are part of the same genetic background.  The wildtype 
littermates effectively serve as a control group for experimental questioning.      
A correlation appears to exist between ABR threshold and DPOAE threshold, 
when the primary frequency f2 is considered; however this is not well understood and 
varies depending on the genetic background of the animals.  Evidence suggests a weak 
correlation between the two measures in non-inbred CD1 mice with early-onset hearing 
loss, compared to a stronger association in C57BL/J6 mice (Parham et al., 2001).  Much 
research is needed in this area to understand better the relationship between these 
measures of auditory function in the mouse.  Investigations using both ABR and DPOAE 
will help to elucidate this relationship and further understanding of their independent and 




There is no direct method, currently, for evaluating the integrity of the middle ear 
system in the mouse.  Immittance measures commonly employed in humans are not 
available yet for use with this species.  Therefore, the risk of peripheral otitis media, 
while not very common, is a distinct possibility.  Measurement of the OAE is dependent 
on both the forward and backward transmission properties of the outer and middle ear, 
and is therefore susceptible to effects of otitis media.  The ABR is also at risk.  Pahram et 
al. (2001) reported a 40 dB elevation in click-evoked ABR thresholds in CBA/J mice 
with otitis media compared to normal controls.  This issue is confounded further by the 
inability to visually inspect the external auditory canal and tympanic membrane for signs 
of infection with hand-held otoscopes.  With the exception of certain background strains 
that are genetically susceptible to otitis media, this is not a common occurrence in 
laboratory mice.  The use of multiple experimental animals should negate the effect of 
any sporadic case(s) of otitis media on collapsed data from the cohort. 
The mouse model of NPC.  The discovery of several animal models of NPC in 
recent years has advanced the ability of researchers to investigate and resolve many 
remaining mysteries of this disease.  Although microbial (Higaki, Almanzar-Paramio, & 
Sturley, 2004) and canine (Bundza, Lowden, & Charlton, 1979) models of NPC exist, 
most research has focused on the feline and mouse models, which both exhibit 
spontaneous genetic mutations homologous to humans with NPC.  Disease 
manifestations are clinically, biochemically, and morphologically comparable between all 
three species (Kolodny, 2000), and the mouse model has emerged as the preeminent 
animal model for NPC.  Two mouse models for mutations in NPC1 exist: BALB/c-




defects in NPC involved the BALB/c strain, and this strain continues to be more widely 
used in various areas of research.  As a result, a great deal is now known about the 
neuropathology of the disease in BALB/c background model. 
The molecular, anatomical, and biochemical manifestations in NPC mice mimic 
those observed in humans with the disease.  NPC mice show age-related Purkinje cell 
loss and demyelination in the corpus callosum (German et al., 2001; Weintraub et al., 
1992).  In addition, neuronal degeneration in the cerebellum and brainstem structures has 
been widely documented in this strain, and is consistent with the onset of tremors and 
ataxia well-noted in the phenotype.  Homozygous mutant offspring have widespread 
cortical degeneration that is both spatially and temporally specific, such that affected 
nerve fibers (e.g., axons) appear to degenerate before cell bodies (Ong et al., 2001).  
There is also evidence for a global reduction in white matter tracts (Ory, 2000).   
Minimal behavioral data have been obtained from the NPC mouse beyond 
describing overt phenotypic manifestations, with the majority of research focusing on the 
metabolic and neuropathological characteristics of the disease.  Võikar, Rauvala, and 
Ikonen (2002) offer a rare description of cognitive deficits and development of motor 
impairments in the (BALB/c) NPC1 mouse.  Male and female homozygous NPC (-/-) 
mice showed retarded growth between p25 and p35.  Their weight was similar to control 
mice up to p45, after which it rapidly decreased.  Motor impairment was present between 
p28 and p42, prior to the onset of visible ataxia.  Diseased mice displayed decreased 
exploratory activity and no habituation, in addition to learning and memory deficits, 
which suggest some degree of cognitive impairment.  In several measures, male         




differences have been reported elsewhere in other neurodegenerative mouse models with 
cerebellar involvement in which female mutant mice were less affected neurologically 
and showed less deterioration in their neuroanatomy than their male counterparts.      
There have been no reports on auditory function in the NPC mouse model.  
However, Luan et al. (2008) documented brainstem pathology localized to the auditory 
pathway in the NPC1 (BALB/c) mouse.   They compared the brainstems of eight-week-
old mutant NPC1 (-/-) mice with a control group of littermates, comprised of carrier 
NPC1 (+/-) and wild type (+/+) mice.  The neural density of the ventral cochlear nucleus 
was significantly lower in mutant mice than controls.  In addition, a proliferation of 
astrocytes was observed in the inferior colliculus and medial geniculate nucleus, which 
the authors suggest is an additional aspect of the neuropathology of NPC.   
Currently, the BALB/cNctr-Npc1m1N/J strain is sold by the Jackson Laboratory 
and has been procured by the National Institutes of Health for study.  This strain of mice, 
hereafter referred to as the BALB/c or NPC1 mouse, begins to show neurological 
symptoms including tremor and ataxic gate, together with poor food intake at 
approximately seven weeks of age.  The life span is approximately 75 days (phenotypic 
information retrieved from the Jackson Laboratory, 1/18/09, 
http://jaxmice.jax.org/strain/003092.html).   
Beyond the advantages previously mentioned, working with the NPC1 mouse to 
help elucidate the auditory phenotype of the disease is attractive for a number of reasons.  
The challenges posed by studying a genetically heterogeneous species, such as humans, 
make quantifying the contribution of a specific genetic mutation challenging.  Extensive 




virtually impossible to find individuals with no exposure to the confounding influences of 
uncontrolled environmental factors.  The short lifespan of the mouse makes it ideal for 
addressing questions of progression.  Similar patterns in the neurological deterioration 
relative to lifespan have been documented in mice and humans with NPC, and there is no 
reason to believe the same would not be true of the auditory phenotype. 
A mouse model for disease not only allows access to longitudinal audiological 
data in a reasonable period of time, but it does so in a controlled manner that is not 
possible when collecting data from humans.  These mice are uniform in their molecular 
composition, they receive the same care and husbandry, and their environmental 
exposures to extraneous influences not only are controlled and limited, but also identical.  
If any of these factors affect the variability in the clinical phenotype observed in humans, 
which is most assuredly the case, then use of the mouse model will, by design, improve 
the likelihood of finding interpretable, meaningful results as compared to 
experimentation focused solely on humans with NPC.      
Based on its molecular, biochemical, and clinical characteristics, the NPC1 
BALB/c mouse strain is an excellent model for describing both normal and abnormal 
function in humans with the disease.  Indeed, many of the heuristic discoveries 
responsible for exposing the molecular and biochemical foundations of NPC have been 
aided or accomplished with the use of this model, and there is no doubt that future 
research, including new potential pharmacological and therapeutic interventions, will 







Experiment one identified an auditory phenotype in humans with NPC; high 
frequency hearing loss is common, and retrocochlear pathology involving the auditory 
brainstem tracts is pervasive.  The hearing loss is progressive in at least some individuals, 
and those with late-onset disease may have auditory manifestations long before overt 
neurologic onset.  It is unclear from the human data whether the neural component of the 
auditory dysfunction is progressive, although longitudinal data from one individual 
suggest it may be.   
A mouse model with a spontaneous genetic mutation homologous to that 
observed in humans exists for NPC.  Much of the phenotype in this model has been 
described previously and closely resembles clinical characteristics observed in humans 
with this disease, indicating it is a good animal model for studying NPC.  However, to 
date, there has been no examination of auditory function in this mouse model.  Detailed 
and comprehensive examination of the auditory manifestations of humans with NPC 
revealed a pattern of dysfunction, despite limitations in the data, and any correlation with 
findings in an animal model will only strengthen that investigation.  It is possible that the 
auditory system may ultimately serve as a clinical marker for the progression of NPC 
and, potentially, as a benchmark for therapeutic intervention.  This will remain 
speculative until impact of the disease on the auditory system is understood fully.  It 
appears that comparative, translational research involving both humans and mice is the 






Research Questions and Hypotheses 
The overarching question is whether or not the pathophysiological processes of 
NPC detrimentally impact auditory system function in the NPC1 mouse and, if so, how 




1. Is there a significant difference in auditory function as measured by ABR 
thresholds and DPOAEs between the three experimental groups: homozygous 
NPC1 mice (-/-), heterozygous carriers (+/-), and wildtype littermates (+/+)? 
a. If auditory function is poorer in NPC1 mutant mice (-/-) than wildtype 
controls, can the site-of-lesion be localized using DPOAEs and ABR? 
b. Is there a significant effect of gender on hearing outcomes (DPOAEs 
and ABR) within the three experimental groups?   
c. Are the auditory findings within each group stable over the course of 
the experimental lifetime? 
Hypotheses 
 
It is hypothesized that NPC1 mutant mice (-/-) will display an abnormal auditory 
phenotype compared to wildtype littermates.  This hypothesis is based on known 
similarities between the phenotype in NPC1 mutant mice (-/-) and humans with this 
disease, and because experiment one identified auditory dysfunction in affected humans.  
DPOAE and ABR data will evaluate the integrity of the auditory pathway through the 
auditory brainstem in this strain and should be sensitive to dysfunction.  These measures 
have been successful in identifying auditory dysfunction in other mouse models for 




histology localized to the auditory brainstem in this strain (Luan, 2008), it is 
hypothesized that dysfunction will at least be localized to the auditory brainstem and may 
manifest as significantly elevated ABR thresholds, prolonged absolute and interpeak 
latencies, and/or decreased waveform amplitude for mutant mice as compared to wildtype 
littermates. Additionally, NPC1 mutant mice are anticipated to have significantly lower 
DPOAE amplitude compared to control animals based on DPOAE and pure-tone 
threshold findings in humans with NPC that indicate a concomitant cochlear site of 
lesion. 
There is no strong evidence to suggest that NPC1 heterozygous carriers (+/-) 
should have poorer hearing than wildtype control mice given the autosomal recessive 
inheritance pattern of the disease.  However, some reports suggest subtle neurological 
dysfunction in heterozygous carriers of the NPC1 mutation in both mice and humans 
(Josephs, Matsumoto, & Lindor, 2004; Yu, Ko, Yanagisawa, & Michikawa, 2005).  
Consequently, their auditory data will be analyzed separately. Significant differences in 
ABR (threshold and latency) and DPOAE data are not anticipated between heterozygous 
carriers (+/-) and wildtype littermates.  Similarly, Võikar et al. (2002) observed 
differences in cognitive and developmental motor function in male and female NPC1 
mice (-/-).  Differences in age-related hearing loss between male and female mice of the 
same strain have also been reported (e.g., Henry, 2004).  This is not a common finding in 
this species, however, and gender differences in auditory function in any of the three 
experimental groups are not anticipated. 
 Given the neurodegenerative nature of the disease, it is hypothesized that the 




experimental lifespan.  Progressive hearing loss would be consistent with other aspects of 
the phenotype reported in this model, including shortened lifespan, progressive ataxia, 
and progressive neurological dysfunction; it would also be consistent with the 
progressive hearing loss observed in humans.  The lifespan of the NPC1 mutant animal is 
approximately 75 days.  The experimental lifespan is expected to be shorter in duration 
and is contingent on the animals’ ability to maintain life independently without 
unnecessary pain or discomfort.  As such, euthanasia criteria have been established and 




Participants.  Heterozygous carriers (+/-) of the NPC1 mutation (BALB/cNctr-
Npc1m1N/J strain) were mated to produce offspring that were homozygous (-/-) for the 
NPC1 mutation, heterozygous carriers (+/-), and wildtype (+/+) littermates.   
 The Animal Care and Use Committee (ACUC) of the University of Maryland 
College Park (R-08-20), and the combined National Institute of Neurological Disorders 
and Stroke and NIDCD ACUC (1264-06) approved this work.  Animals were housed at 
an NIH facility in Rockville, Maryland, and maintenance and care of the animals 
followed the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory 
Animal Resources, Committee on Care and Use of Laboratory Animals, 1985).  Twenty 
mice per group (genotype) were used in this experiment, for a total of 60 mice.  The 
experimenter was blinded to the genotype of the animals during the early part of life prior 




 Equipment.  DPOAEs were recorded with an ER-10C (Etymotic Research) 
speaker-probe assembly using the DP2000 DPOAE measurement system, version 3.0 
(Starkey Laboratories).  ABR stimuli were generated with the auditory-evoked Intelligent 
Hearing Systems (IHS) software and produced through a high-frequency, ear-specific 
transducer.     
Procedure.  Animals were anesthetized using a combined cocktail of ketamine 
and dormitor, administered via subcutaneous (SQ) injection.  Total dosage of anesthesia 
was weight-dependent, and neither of these drugs is known to affect auditory function in 
this species.  In order to protect the corneas of the mice while under sedation, an otic 
cream was applied to the animals’ eyes.  The postauricular areas of skin and head of the 
mouse were cleaned with disposable alcoholic wipes.  The animal was placed on a 
heating pad in a sound-treated test booth.  A thermometer ensured the temperature of the 
heating pad was maintained at 37 degrees Fahrenheit to preserve the body heat of the 
animal.   
DPOAEs were recorded by placing the speaker-probe assembly in the external 
auditory canal of the animal.  Two primary tones at a frequency ratio (f2/f1) of 1.2 were 
presented at L1 = 65 dB SPL and L2 = 55 dB SPL.  Calibration of the primary tones took 
place in situ.  The primary tones were varied in one-twelfth octave steps from 5297 to 
10641 Hz, based on the frequency limitations of the speaker-probe assembly.  DPOAE 
data were collected on both ears of each animal.   
ABRs were evaluated by placing three subdermal needle electrodes: one at the 
forehead and one at each mastoid location.  ABR thresholds were averaged using a 




Averages were acquired at a rate of 21 per second, and a minimum of 400 artifact-free 
averages were obtained for each recording.  Prior to beginning threshold searches, a high 
intensity (e.g., 110 dB SPL) suprathreshold response was collected and used to determine 
absolute and interpeak latencies, as well as waveform amplitude.  The same number of 
averages (1024) was collected for the high intensity responses for every test session on 
each animal.  
Threshold search began with administration of a 110 dB SPL signal for the click, 
8, and 16 k Hz stimuli, and a 100 dB SPL signal for the 32k Hz tone burst.  The stimulus 
intensity was decreased subsequently in 10 dB steps, followed by 5 dB steps at lower 
intensities near threshold, to determine the exact threshold of the response.  Once 
threshold was reached, the response was repeated to determine replicability.  Following 
collection of suprathreshold data and determination of thresholds for click and tone burst 
stimuli, the effects of sedation were reversed using an antecedent and the animal was 
returned to a recovery cage.  
In light of the neurodegenerative phenotype, endpoint criteria for euthanasia were 
established to ensure that none of the animals suffered unnecessarily.  They were as 
follows: 15% loss of total body weight or an observation that the animal was moribund, 
cachectic, or unable to obtain food or water.  The animals were monitored daily by 
trained staff.  No additional husbandry care (e.g., bladder secretion, intravenous delivery 
of food) was provided once endpoint criteria were met.  Therefore, the temporal intervals 
of the experimental design were contingent on the lifespan and neurological condition of 




Based on these criteria, the experimental lifespan of the NPC1 mutant (-/-) mice 
extended to p65.  All mice were able to survive to this age; however, very few mutant 
animals were able to survive to p70 without meeting euthanasia criteria and requiring 
additional husbandry care.  The timeframe for auditory testing was also limited by the 
development of the auditory system and weaning from the mother.  The auditory system 
in the mouse is mature at approximately p17, and weaning usually occurs around p20.  
Therefore auditory testing began at p20 and was repeated every five days until p65, 
resulting in 10 longitudinal data points.   
Five-day time intervals were selected based on the health and well being of the 
animals.  Full recovery of the animals from anesthesia precludes testing at very short time 
intervals.  Because auditory findings in NPC mice have not been published, guidance on 
a longitudinal test schedule was derived from longitudinal studies of other neurological 
measures in this mouse model.  Võikar et al. (2002) observed longitudinal changes in 
cognitive function and motor impairment in NPC mice that were tested every seven days 
starting at P28 and ending at day P56.  Significant changes in performance could be noted 
between individual test sessions, indicating that a five-day test interval of auditory 
function was reasonable and likely to produce meaningful data without causing 
unnecessary stress for the animals. 
Statistical Analysis.  Data were maintained and analyzed using Microsft Excel, 
the Statistical Package for Social Sciences Software (SPSS, v15) and the Proc MIXED 
SAS 9.1 software packages.  For all statistical analyses, α = .05.  Descriptive statistical 




To evaluate neural and cochlear function, change over time, and effect of disease 
within gender, DPOAE (averaged between the right and left ears) and ABR data were 
analyzed using a repeated measures model with auto-regressive correlation matrix 
structure (e.g., Crowder & Hand, 1990).  This is similar to a typical repeated measures 
ANOVA but models time as an interval-scaled variable rather than a nominal-scaled 
variable.  A typical repeated measures ANOVA requires the assumption of sphericity, 
typically modeled as compound symmetry.  Compound symmetry assumes that the 
correlation between residuals (i.e., what remains after main effects and interactions 
between genotype, test time, and gender are accounted for) for any two repeated 
measures is the same across the experimental lifespan.  The autoregressive structure 
postulates that the correlation is stronger between time points that are closer together, and 
weaker between time points that are farther apart.  Both the auto-regressive and 
compound symmetry approaches assume that un-modeled characteristics have a similar 
effect for multiple measures, but auto-regression allows for these relationships to change 
over time (e.g., a mouse with ‘good’ hearing at p20 is likely to still have good hearing at 
p25, but this may be less likely by p65).  Fit statistics for both auto-regressive and 
compound symmetry models were generated to determine how strongly the data appear 
to correlate with a given model, and the fit was better for the auto-regressive approach.  
This confirms the logical assumption that the auto-regressive model is more appropriate 
than the compound symmetry model for this dataset. 
DPOAE level and ABR (click and tone pip) threshold, suprathreshold latency 
(absolute and interpeak), and amplitude data were evaluated in separate analyses.  For all 




Y = intercept + Gender + Genotype (Homozygous/Non-Homozygous) + Time + all 
interactions  
Preliminary analyses revealed no significant differences in measures of hearing 
(DPOAE level, ABR threshold, latency, amplitude) between heterozygous carriers (+/-) 
and wildtype (+/+) littermates.  Therefore, these data were pooled to increase power.  The 
non-mutant mouse (+/-, +/+) group will be referred to in this document as control 
animals for comparison to mutant (-/-) data. 
Pitfalls.  Following collection of nearly three-quarters of the data an 
unexplainable shift in 8k Hz threshold data was observed.  Specifically, thresholds across 
animals seemed notably lower (better) than those collected previously.  Ultimately, it was 
discovered that another NIH investigator using the shared equipment uncovered a filter 
box and changed the setting from “High Pass” to “Direct.”  Until this point, all data had 
been collected using the “High Pass” filter setting.  This was not the appropriate filter 
setting for an 8k Hz stimulus, and the presence of the filter was not apparent to the 
investigative team. 
A discussion with the manufacturer (IHS) of the effects of the change in filter 
setting revealed that 8k Hz data collected with the filter on (High Pass) results in a loss of 
stimulus intensity; in other words, 8k Hz thresholds collected with the filter on (High 
Pass) will be higher (poorer) than those collected with the filter off (Direct).  The 
manufacturer is unaware of any negative effect of having the filter on when collecting 
16k and 32k Hz data, and in fact recommends this setting when using these stimuli. 
Data collected during the time between the noticeable shift in thresholds and the 




possible discrepancy in data collected with different filter settings, it was decided (via 
personal communication with SGS, CB, and KK) that all remaining 8k Hz data would be 
collected twice: once with the filter turned on (High Pass), and once with the filter turned 
off (Direct).  The aim was to develop a correction factor for all previous data collected a 
posteriori.   
Following completion of data collection, 8k Hz data were analyzed to determine 
if the effect of the filter box was consistent between genotypes and across hearing 
thresholds.  A consistent finding would suggest that a correction factor could be applied 
to data collected with the Direct filter setting.  However, results revealed an effect of 
genotype; the difference between the High Pass and Direct settings is approximately 4 dB 
larger for wildtype (+/+) than for homozygous (-/-) mice and the effect varied depending 
on the threshold for hearing.  Therefore, no correction factor was applied and all 8k Hz 
data reported for this study represent those data collected with the filter on High Pass.  
Results   
Twenty mice from each experimental (genotype) group were evaluated starting at 
p20 every five days until p65, for a total of 60 mice with 10 longitudinal data points.  
Sporadic data points are missing due to uncontrollable circumstance (e.g., problems with 
sedation); in total, 575 test sessions occurred.  Demographic data, including genotype, are 
included in Figure 28.  Animal weight (grams) as a function of age is plotted in Figure 
29.  As expected, mutant (-/-) mice weighed less than control animals (-/+, +/+) across 
the experimental lifespan.  While control animals continued to gain weight, mutant mice 
reached their peak weight at approximately p40 after which they maintained and 





Figure 28. Number of mice by genotype and gender for homozygous (-/-), heterozygous 
(+/-), and wildtype (+/+) NPC1 littermates.   
 
 
Figure 29.  Mean (SD) weight for homozygous (-/-), heterozygous (+/-), and wildtype 




DPOAE Findings.  Mean (SD) DPOAE level and noise floor for mutant and 
control animals are presented in Figure 30.  Both groups had relatively robust signal-to-
noise ratios (SNR) across the experimental life span with the exception of the lowest 
frequency tested (5297 Hz) in the mutant group at p20; however, the SNR at this 
frequency was noted to improve by p65.   
Statistical results of the repeated measures model for DPOAE level for the mutant 
and control groups are presented in Table X.  This table includes data and statistical 
results displayed in three columns: A, B, and C.  Column A shows estimates of DPOAE 
level (dB SPL) by frequency for  mutant (-/-) and control animals (+/- +/+) at p20, and 
the effect of disease (genotype) at that point in time (F-statistic, degrees of freedom, p-
value). At p20 mutant animals have significantly lower DPOAE levels than control 
animals at all test frequencies except for 10641 Hz (p=0.05) and 7547 Hz (p=0.13).  This 
is not a true main effect as it is conceived in a typical ANOVA, which is time-invariant, 
but rather an effect of disease ‘within’ a value of time (e.g., p20).  Column B shows the 
estimates of progression in DPOAE level (dB) for mutant and control animals per five-
day test session; positive values indicate an increase in DPOAE level, and negative 
values indicate a decrease in DPOAE level every five days.  Statistical results examining 
the significance of the progression within genotype (first two columns within Column B), 
as well as the significance of genotype on progression of DPOAE level (last two columns 
within Column B) are shown.  It is noted that while there is a significant progression of 
DPOAE level for the control group at each frequency and for the mutant group at the 
lower frequencies, there is not a significant difference between the two groups in DPOAE 




SPL) for mutant and control animals at p65, and the effect of disease at that point in time.  
Estimates provided for p20 and p65 in columns A and C, respectively, are drawn from 
the repeated measures model that includes the entire data set at all time points to provide 
an observation at the beginning and end of the experimental lifespan.  These do not 
represent simple analyses (e.g., t-tests) between observations at test time one and test 
time 10.  Column C indicates that at p65, mutant animals continue to have significantly 








Figure 30.  Mean (SD) DPOAE level (solid lines) for mutant (-/-) and control (+/-, +/+) 





Table X. Results of repeated measures analyses for DPOAE level (dB SPL) at p20 and p65, and DPOAE level progression data (dB). 
 
*   significant at p<.05 level 
** significant at p<.01 level 
Note. (df, df), degrees of freedom numerator, degrees of freedom denominator.
 (A) p20 DPOAE level (B) DPOAE level progression/5 days (C) p65 DPOAE Level 
Hz -/- +/- +/+ F  
(df, df) 
p value     -/-   
(p value) 




p value -/- +/- +/+ F  
(df, df) 
p value 
10641 27.2 28.9 4.01 
(1, 56) 






0.4478 29.0 31.6 10.34 
(1, 56) 
0.0022** 
9797 29.5 32.2 13.28 
(1, 56) 






0.1528 30.1 34.4 35.21 
(1, 56) 
<.0001** 
8953 28.7 31.8 16.42 
(1, 56) 






0.1344 29.4 34.3 40.64 
(1, 56) 
<.0001** 
8203 22.8 28.9 32.14 
(1, 56) 






0.6187 24.7 30.6 41.68 
(1, 56) 
<.0001** 
7547 19.3 21.8 2.43 
(1, 56) 






0.0908 19.2 26.3 19.61 
(1, 56) 
<.0001** 
6891 7.6 15.1 34.99 
(1, 56) 






0.6625 18.3 24.8 27.43 
(1, 56) 
<.0001** 
6328 1.0 9.8 44.05 
(1, 56) 






0.4369 14.8 22.0 29.43 
(1, 56) 
<.0001** 
5813 -6.5 3.8 57.22 
(1, 56) 






0.3615 6.8 15.1 37.85 
(1, 56) 
<.0001** 
















Table XI evaluates the effect of disease, as well as the relationship 
between gender and test-time for DPOAE level data, separately for male and 
female mice. This is not a typical examination of main and interaction effects of 
gender, disease, and time, but rather tests the effects of interest (disease and 
disease*time) at all levels of the blocking variable gender.  Exploring differences 
between male mice and female mice simply identifies differences between mice, 
but does not identify effects of disease.  Therefore, these comparisons were 
established to observe the effect of disease within gender; specifically, the effect 
of disease within male mice and the effect of disease within female mice.  Table 
XI is also displayed in three columns: A, B, and C.  Column A shows the 
statistical comparison between mice with (-/-) and without (+/- +/+) disease (F-
statistic, degrees of freedom, p-value) for females and  males at p20.  Column B 
compares the progression of DPOAE level every five days in mice with and 
without disease for females and males.  Column C shows the comparison between 
mice with and without disease for females and males at p65. 
 There is no consistent difference in the effect of disease within genders 
observed on DPOAE level across the experimental lifespan.  That is, when 
significant effects of disease between mutant animals and control animals are 
observed (Table X), these occur for both female and male mice at most test 
frequencies across the experimental lifespan.  An exception to this is DPOAE 
level at p20 at 8953 Hz, and DPOAE progression and level at p65 at 7547 Hz, 




Table XI. Results of repeated measures analyses examining effects of disease within gender and test time for DPOAE level. 
Comparisons are between female and male mice with (-/-) and without (+/- +/+) disease. 
 (A) p20 DPOAE Level (B) DPOAE level progression/5 days (C) p65 DPOAE Level 
 Female Male Female Male Female Male 
Hz F  
(df, df) 
p value F  
(df, df) 
p value F  
(df, df) 
p value F  
(df, df) 
P value F  
(df, df) 
























































































































             
*   significant at p<.05 level 
** significant at p<.01 level 




ABR Threshold Findings.  ABR threshold data at p20 and p65 for all genotypes 
for click, 8k, 16k, and 32k Hz stimuli are shown in Figure 31.  Results of initial repeated 
measures modeling revealed that the mutant group exhibited higher (poorer) thresholds 
than control animals at p20 for 16k and 32k Hz, and at p65 for all stimuli.  Because no 
significant differences in ABR thresholds were observed between heterozygous (+/-) and 
wildtype (+/+) animals, their data were collapsed for additional analyses. Results of 
follow-up repeated measures modeling (two experimental groups: collapsed control 
group and mutant group) for ABR threshold comparing the mutant and control groups are 
presented in Table XII.  For a detailed explanation of table formatting, refer to DPOAE 
level results described on pages 116 and 117.  Threshold data are provided in dB SPL.  
Positive progression estimates (dB) indicate an increase in threshold and negative values 
indicate a decrease in threshold every five days.  
At p20 (Table XII, Column A), mutant animals have significantly poorer hearing 
than control animals at 16k Hz and 32k Hz.  By p65, mutant mice have significantly 
poorer hearing as measured by the ABR threshold across all test stimuli compared to 
control animals.  Mutant animals exhibit a significant progression in ABR click threshold 
at a rate of 0.32 dB/ 5 days with no significant change in hearing among the control 
animal group over the time span of the experiment.  For 8k Hz and 16k Hz stimuli, 
thresholds of the mutant animals become progressively poorer at rates of .4 and .7 dB/5 
days, respectively, with no significant change in threshold in control animals.  At 32k Hz, 
mutant animals do not exhibit progression in their hearing thresholds, but control animals 
do at a rate of 3.6 dB/5days.  Despite this progression in the non-mutant group, mutant 




compared to control animals.  The progression observed in ABR stimuli by genotype is 
shown in Figures 32 and 33.  Results of the repeated measures modeling examining 
differences between groups at each test interval are provided in Tables XIII, XIV, XV, 
and XVI (click, 8k, 16k, and 32k Hz analyses, respectively).  The progression in 
threshold of mutant animals observed for click and 8k Hz ABR stimuli results in 
significant differences between mutant and control animals at p35, which continues 
through the remainder of the experimental lifespan. ABR thresholds at 16k and 32k Hz in 






Figure 31.  Mean (SD) ABR thresholds for homozygous (-/-), heterozygous (+/-), and 
wildtype (+/+) NPC1 littermates at p20 (top panel) and p65 (bottom panel).    




Table XII. Results of repeated measures analyses for ABR threshold (dB SPL) at p20 and p65, and ABR threshold progression data 
(dB). 
 
*   significant at p<.05 level 
** significant at p<.01 level 





             (A) p20 Threshold (B) Threshold progression/5 days (C) p65 Threshold 
 -/- +/- +/+ F  
(df, df) 
p value    -/-   
(p value) 




p value -/- +/- +/+ F  
(df, df) 
p value 








0.0196* 45.40 41.78 18.15 
(1, 56) 
<.0001** 








0.0177* 50.41 46.27 16.94 
(1, 56) 
0.0001** 








0.0299* 39.96 31.66 36.98 
(1, 56) 
<.0001** 








<.0001** 56.60 50.21 16.26 
(1, 56) 
0.0002** 






Figure 32.  Mean ABR threshold data for click (top panel) and 8k Hz (bottom panel) 










Figure 33.  Mean ABR threshold data for 16k (top panel) and 32k Hz (bottom panel) 







Table XII. Results of repeated measures analysis by test time for click ABR threshold. 






p value  
p20 42.55 42.21 0.15 
(1, 56) 
0.6981  
p25 42.86 42.17 0.92 
(1, 56) 
0.3428  
p30 43.18 42.12 2.93 
(1, 56) 
0.0923  
p35 43.50 42.07 7.10 
(1, 56) 
0.0101*  
p40 43.81 42.02 13.51 
(1, 56) 
0.0005**  
p45 44.13 41.97 19.62 
(1, 56) 
<.0001**  
p50 44.45 41.93 22.31 
(1, 56) 
<.0001**  
p55 44.76 41.88 21.83 
(1, 56) 
<.0001**  
p60 45.08 41.83 20.07 
(1, 56) 
<.0001**  




*   significant at p<.05 level 
** significant at p<.01 level 





















p value  
p20 46.52 46.33 0.03 
(1, 56) 
0.8529  
p25 46.95 46.33 0.53 
(1, 56) 
0.4705  
p30 47.38 46.32 2.11 
(1, 56) 
0.1523  
p35 47.82 46.31 5.62 
(1, 56) 
0.0212*  
p40 48.25 46.31 11.32 
(1, 56) 
0.0014**  
p45 48.68 46.30 17.05 
(1, 56) 
0.0001**  
p50 49.12 46.29 19.89 
(1, 56) 
<.0001**  
p55 49.55 46.29 19.84 
(1, 56) 
<.0001**  
p60 49.98 46.28 18.51 
(1, 56) 
<.0001**  




*   significant at p<.05 level 
** significant at p<.01 level 





















p value  
p20 33.39 29.83 6.80 
(1, 56) 
0.0117*  
p25 34.12 30.04 11.93 
(1, 56) 
0.0011**  
p30 34.85 30.24 20.25 
(1, 56) 
<.0001**  
p35 35.58 30.45 32.32 
(1, 56) 
<.0001**  
p40 36.31 30.66 45.85 
(1, 56) 
<.0001**  
p45 37.04 30.86 54.83 
(1, 56) 
<.0001**  
p50 37.78 31.07 55.39 
(1, 56) 
<.0001**  
p55 38.50 31.27 50.12 
(1, 56) 
<.0001**  
p60 39.23 31.48 43.26 
(1, 56) 
<.0001**  




*   significant at p<.05 level 
** significant at p<.01 level 





















p value  
p20 54.15 17.87 520.06 
(1, 56) 
<.0001**  
p25 54.42 21.46 573.28 
(1, 56) 
<.0001**  
p30 54.69 25.06 619. 70 
(1, 56) 
<.0001**  
p35 54.97 28.65 630.33 
(1, 56) 
<.0001**  
p40 55.24 32.24 563.36 
(1, 56) 
<.0001**  
p45 55.51 35.83 413. 05 
(1, 56) 
<.0001**  
p50 55.79 39.43 244.44 
(1, 56) 
<.0001**  
p55 56.06 43.02 120.52 
(1, 56) 
<.0001**  
p60 56.33 46.61 50.11 
(1, 56) 
<.0001**  




*   significant at p<.05 level 
** significant at p<.01 level 











There was no consistent effect of disease on gender distinguishing male from 
female mice for the majority of the ABR threshold data (Table XVII).  For 16k Hz 
stimuli at p20, and for click stimuli progression, there is an effect of disease observed in 
female mice but not in male mice.  The reverse is true for 8k and 16k progression data.  




Table XVII. Results of repeated measures analyses examining effects of disease within gender and test time for ABR threshold. 
Comparisons are between female and male mice with (-/-) and without (+/- +/+) disease. 
 (A) p20 Threshold (B) Threshold progression/5 days (C) p65 Threshold 
 Female Male Female Male Female Male 
 F  
(df, df) 
p value F  
(df, df) 
P value F  
(df, df) 
p value F  
(df, df) 
p value F  
(df, df) 
p value F  
(df, df) 
p value 





















































             
*   significant at p<.05 level 
** significant at p<.01 level 




ABR Latency Findings. Results of repeated measures modeling for ABR absolute 
and interpeak latency data are included in Table XVIII (click), Table XIX (8k Hz), Table 
XX (16k Hz), and Table XXI (32 Hz).  See pages 116 and 117 for a detailed description 
of table formatting.  Latency data are provided in ms.  Positive progression estimates 
indicate an increase in latency, and negative values indicate a decrease in latency every 
five days.  
For the click stimulus (Table XVIII), there were no significant differences in 
latency at p20 between mutant and control animals, and latency data from mutant animals 
did not change significantly over time, with the exception of a slight increase (.005 ms/5 
days) in latency at wave I.  Conversely, control animals exhibited a significant decrease 
in latency across all variables.  In general, the effect was greater for later occurring 
waves.  Observation of a decrease in ABR absolute latency early in life is typically 
associated with maturational changes (e.g., myelination of the auditory nerve).  This 
shortening in the latency of control animals resulted in mutant mice having significantly 
longer latencies than control animals by p65 across all variables.   
A similar pattern as the one observed for click latency data was seen for other 
ABR stimuli (Tables XIX, XX, and XXI).  That is, very few differences in latency 
existed between control and mutant animals at p20.  No difference was observed at 16k 
Hz, and of the six absolute latencies that were different between groups at 8k and 32k Hz, 
all but one (wave II, 8k Hz) revealed that mutant mice had longer latencies than control 
animals.  The more robust finding, however, was that for all ABR stimuli, control 
animals underwent a significant decrease in latency across the experimental lifespan in all 




generally greater for later occurring waves.  Mutant mice, however, underwent far fewer 
significant changes in latency over this time period, and most changes involved a 
prolongation in the absolute latency of early waves, resulting in a decrease in interpeak 
latency.  The result of these progressive shifts in latency was that mutant mice had 
significantly longer latencies than control animals for all but three (29/32) ABR latency 
variables at p65.   
ABR mean (SD) absolute latency data as a function of ABR wave component are 
shown separately for the mutant and control groups at p20 and p65 for 8k, 16k, and 32k  
Hz in Figures 34 through 36.  In general, these figures show a decrease in latency, 
especially for the later waves, for the control group at p65 compared to p20.  An example 
of the significant changes in latency observed over time, including a larger effect for later 




Table XVIII. Results of repeated measures analyses for ABR latency (ms) at p20 and p65, and ABR latency progression data (dB) for 
click stimuli. 
 
*   significant at p<.05 level 
** significant at p<.01 level 
Note. (df, df), degrees of freedom numerator, degrees of freedom denominator. 
 (A) p20 Latency  (B) Latency progression/5 days (C) p65 Latency 
Click -/- +/- +/+ F  
(df, df) 
p value      -/-   
(p value) 




p value -/- +/- +/+ F  
(df, df) 
p value 
I 1.37 1.37 0.16  
(1, 56) 






0.8004 1.42 1.33 41.00  
(1, 56) 
<.0001** 
II 2.14 2.20 2.07   
(1, 56) 






0.0002** 2.11 1.91 23.32 
(1, 56)  
<.0001** 
III 3.23 3.17 0.94  
(1, 56) 






0.0797 3.23 2.97 15.16  
(1, 56) 
0.0003** 
IV 4.21 4.18 0.22   
(1, 56) 






0.0019** 4.21 3.83 33.27  
(1, 56) 
<.0001** 
V 5.10 5.02 0.97   
(1, 56) 






0.0002** 5.03 4.44 53.89  
(1, 56) 
<.0001** 
I-III 1.86 1.80 0.81   
(1, 56) 






0.3039 1.81 1.64 6.89  
(1, 56) 
<.0001** 
III-V 1.87 1.83 0.28  
(1, 56) 






0.0153* 1.80 1.47 21.74  
(1, 56) 
<.0001** 
I-V 3.73 3.65 0.96   
(1, 56) 












Table XIX. Results of repeated measures analyses for ABR latency (ms) at p20 and p65, and ABR latency progression data (dB) for 
8k Hz stimuli. 
*   significant at p<.05 level 
** significant at p<.01 level   
Note. (df, df), degrees of freedom numerator, degrees of freedom denominator. 
 (A) p20 Latency (B) Latency progression/5 days (C) p65 Latency 
8k -/- +/- +/+ F  
(df, df) 
p value    -/-   
(p value) 




p value -/- +/- +/+ F  
(df, df) 
p value 








<.0001** 1.75 1.63 55.08 
(1, 56) 
<.0001** 








<.0001** 2.46 2.29 19.67 
(1, 56) 
<.0001** 








<.0001** 3.63 3.22 114.03 
(1, 56) 
<.0001** 








<.0001** 4.69 4.26 80.16 
(1, 56) 
<.0001** 








0.0008** 5.49 4.93 74.25 
(1, 56) 
<.0001** 








0.0007** 1.87 1.59 67.49 
(1, 56) 
<.0001** 








0.5859 1.86 1.70 7.22 
(1, 56) 
0.0095** 














Table XX. Results of repeated measures analyses for ABR latency (ms) at p20 and p65, and ABR latency progression data (dB) for 
16k Hz stimuli. 
 
*   significant at p<.05 level 
** significant at p<.01 level   
Note. (df, df), degrees of freedom numerator, degrees of freedom denominator. 
 (A) p20 Latency (B) Latency progression/5 days (C) p65 Latency 
16k -/- +/- +/+ F  
(df, df) 
p value    -/-   
(p value) 




p value -/- +/- +/+ F  
(df, df) 
p value 








<.0001** 1.62 1.52 44.48 
(1, 56) 
<.0001** 








0.7895 2.33 2.33 0.00 
(1, 56) 
0.9655 








0.6774 3.31 3.23 2.02 
(1, 56) 
0.1610 








0.0275* 4.40 4.05 27.09 
(1, 56) 
<.0001** 








0.0002** 5.26 4.76 47.32 
(1, 56) 
<.0001** 








0.7332 1.73 1.70 0.23 
(1, 56) 
0.6355 








0.0004** 1.96 1.55 35.79 
(1, 56) 
<.0001** 














Table XXI. Results of repeated measures analyses for ABR latency (ms) at p20 and p65, and ABR latency progression data (dB) for 
32k Hz stimuli. 
 
*   significant at p<.05 level 
** significant at p<.01 level   
Note. (df, df), degrees of freedom numerator, degrees of freedom denominator.
 (A) p20 Latency (B) Latency progression/5 days (C) p65 Latency 
32k -/- +/- +/+ F  
(df, df) 
p value    -/-   
(p value) 




p value -/- +/- +/+ F  
(df, df) 
p value 








0.0049** 1.75 1.56 73.76 
(1, 56) 
<.0001** 








0.0213* 2.54 2.33 13.86 
(1, 56) 
0.0005** 








0.0003** 3.50 3.21 48.48 
(1, 56) 
<.0001** 








<.0001** 4.59 4.08 84.84 
(1, 56) 
<.0001** 






0.0005** 5.43 4.89 73.77 
(1, 56) 
<.0001** 








0.0054** 1.75 1.64 9.07 
(1, 56) 
0.0039** 








0.2131 1.93 1.69 20.03 
(1, 56) 
<.0001** 




















Figure 34.  ABR mean (SD) absolute latency data at 8k Hz for mutant (top panel) and 







Figure 35. ABR mean (SD) absolute latency data at 16 kHz for mutant (top panel) and 








Figure 36. ABR mean (SD) absolute latency data at 32 kHz for mutant (top panel) and 









Figure 37.  ABR mean latency data for mutant (-/-) and control (+/-, +/+) animals across 













Effects of disease within gender were not observed consistently across waveform 
absolute or interpeak latency variables (Tables XXII, XXIII, XXIV, XXV); however, 
sporadic effects of disease within gender were identified.  For the click stimulus (Table 
XXII), effects of disease within gender were observed for progression of waves III and 
IV and interpeak III-V, and at p65 for wave III and interpeak I-III.  Effects of disease 
within gender were observed for 8k Hz stimuli (Table XXIII) at p20 for wave V, for 
progression of wave V and interpeak I-III and I-V, and at p65 for interpeak I-III.  For 16k 
Hz stimuli (Table XXIV), effects of disease within gender were observed at p65 for wave 
III.  Effects of disease within gender were observed for 32k Hz stimuli (Table XXV) at 
p20 for waves IV and V and interpeak III-V, for progression of waves I and II, and at p65 
for wave II and interpeak I-III.  Of the 18 variables at which an effect of disease was 
observed within one gender and not the other, 17 of these were identified effects of 




Table XXII. Results of repeated measures analyses examining effects of disease within gender and test time for ABR latency for click 
stimuli.  Comparisons are between female and male mice with (-/-) and without (+/- +/+) disease. 
 (A) p20 Latency (B) Latency progression/5 days (C) p65 Latency 
Click Female Male Female Male Female Male 
 F  
(df, df) 
p value F  
(df, df) 
p value F  
(df, df) 
p value F  
(df, df) 
p value F  
(df, df) 
p value F  
(df, df) 
p value 









































































































*   significant at p<.05 level 
** significant at p<.01 level 




Table XXIII. Results of repeated measures analyses examining effects of disease within gender and test time for ABR latency for an 
8k Hz stimulus.  Comparisons are between female and male mice with (-/-) and without (+/- +/+) disease. 
 (A) p20 Latency (B) Latency progression/5 days (C) p65 Latency 
8k Female Male Female Male Female Male 
 F  
(df, df) 
p value F  
(df, df) 
p value F  
(df, df) 
p value F  
(df, df) 
p value F  
(df, df) 
p value F  
(df, df) 
p value 













































































































*   significant at p<.05 level 
** significant at p<.01 level 




Table XXIV. Results of repeated measures analyses examining effects of disease within gender and test time for ABR latency for a 
16k Hz stimulus.  Comparisons are between female and male mice with (-/-) and without (+/- +/+) disease. 
 (A) p20 Latency (B) Latency progression/5 days (C) p65 Latency 
16k Female Male Female Male Female Male 
 F  
(df, df) 
p value F  
(df, df) 
p value F  
(df, df) 
p value F  
(df, df) 
p value F  
(df, df) 
p value F  
(df, df) 
p value 













































































































*   significant at p<.05 level 
** significant at p<.01 level 




Table XXV. Results of repeated measures analyses examining effects of disease within gender and test time for ABR latency for a 32k 
Hz stimulus.  Comparisons are between female and male mice with (-/-) and without (+/- +/+) disease. 
 (A) p20 Latency (B) Latency progression/5 days (C) p65 Latency 
32k Female Male Female Male Female Male 
 F  
(df, df) 
p value F  
(df, df) 
p value F  
(df, df) 
p value F  
(df, df) 
p value F  
(df, df) 
p value F  
(df, df) 
p value 











































































































*   significant at p<.05 level 
** significant at p<.01 level 




ABR Amplitude Findings. Results of repeated measures modeling for ABR 
amplitude data are included in table XXVI (click), table XXVII (8k Hz), table XXVIII 
(16k Hz), and table XXIX (32 Hz).  See pages 116 and 117 for a detailed description of 
table formatting.  Amplitude data are provided in microvolts.  Positive progression 
estimates indicate an increase in amplitude, and negative values indicate a decrease in 
amplitude every five days.  
For click and 8k Hz stimuli, both mutant and control animals exhibit progressive 
decrease in amplitude across most component peaks of the ABR over the experimental 
time period.  While there are sporadic waveforms that are significantly different in 
amplitude between the two groups at both p20 and p65, a clear pattern is not apparent.  
That is, mutant mice have both smaller and larger amplitudes than control animals for 
various components of the ABR waveform.  At 16k and 32k Hz, mutant and control 
animals both show a progressive decline in amplitude (i.e., decline in synchronized 
neural activity) over the experimental lifespan, but at each of these frequencies, mutant 
mice have smaller amplitude waveforms at most peaks both at p20 and p65.  Notably, 
16k and 32k Hz are the test frequencies with the greatest difference in hearing (ABR 




Table XXVI. Results of repeated measures analyses for ABR amplitude (µV) at p20 and p65, and ABR amplitude progression data 
(µV) for click stimuli. 
 
*   significant at p<.05 level 
** significant at p<.01 level   




 (A) p20 Amplitude (B) Amplitude progression/5 days (C) p65 Amplitude 
Click -/- +/- +/+ F  
(df, df) 
p value    -/-   
(p value) 




p value -/- +/- +/+ F  
(df, df) 
p value 





















0.0412* 0.92 0.84 0.45 
(1, 56) 
0.5051 








0.1265 0.36 0.74 17.58 
(1, 56) 
<.0001** 








0.5226 0.71 0.49 5.84 
(1, 56) 
0.0189* 








0.5826 0.76 0.85 1.41 
(1, 56) 
0.2408 




Table XXVIII. Results of repeated measures analyses for ABR amplitude (µV) at p20 and p65, and ABR amplitude progression data 
(µV) for 8k Hz stimuli. 
 
*   significant at p<.05 level 
** significant at p<.01 level   





 (A) p20 Amplitude (B) Amplitude progression/5 days (C) p65 Amplitude 
8k -/- +/- +/+ F  
(df, df) 
p value    -/-   
(p value) 




p value -/- +/- +/+ F  
(df, df) 
p value 








0.1120 1.82 1.18 6.72 
(1, 56) 
0.0122* 








0.3028 1.03 0.75 7.31 
(1, 56) 
0.0090** 








0.1410 0.23 0.63 17.98 
(1, 56) 
<.0001** 








0.0081** 0.59 0.46 2.93 
(1, 56) 
0.0927 








0.9602 0.50 0.46 0.38 
(1, 56) 
0.5384 




Table XXX. Results of repeated measures analyses for ABR amplitude (µV) at p20 and p65, and ABR amplitude progression data 
(µV) for 16k Hz stimuli. 
 
*   significant at p<.05 level 
** significant at p<.01 level   





 (A) p20 Amplitude (B) Amplitude progression/5 days (C) p65 Amplitude 
16k -/- +/- +/+ F  
(df, df) 
p value    -/-   
(p value) 




p value -/- +/- +/+ F  
(df, df) 
p value 








0.0002** 1.65 1.68 0.01 
(1, 56) 
0.9114 








0.0188* 0.64 0.92 4.32 
(1, 56) 
0.0423* 








0.7697 0.44 0.62 4.03 
(1, 56) 
0.0494* 








0.7351 0.57 0.53 0.29 
(1, 56) 
0.5964 








0.7165 0.60 0.70 1.40 
(1, 56) 
0.2424 




Table XXXII. Results of repeated measures analyses for ABR amplitude (µV) at p20 and p65, and ABR amplitude progression data 
(µV) for 32k Hz stimuli. 
 
*   significant at p<.05 level 
** significant at p<.01 level   




 (A) p20 Amplitude (B) Amplitude progression/5 days (C) p65 Amplitude 
32k -/- +/- +/+ F  
(df, df) 
p value    -/-   
(p value) 




p value -/- +/- +/+ F  
(df, df) 
p value 








0.0024** 0.78 1.57 18.30 
(1, 56) 
<.0001** 








0.0976 0.92 1.25 7.68 
(1, 56) 
0.0076** 








0.3695 0.40 0.58 5.08 
(1, 56) 
0.0281* 








0.5152 0.47 0.53 0.93 
(1, 56) 
0.3396 








0.1361 0.51 0.62 2.56 
(1, 56) 
0.1150 




Similar to the latency data, effects of disease within gender were not consistently 
observed across waveform amplitude variables.  Sporadic effects of disease within gender 
were identified.  For the click stimulus (Table XXX) effects of disease within gender 
were observed at p20 for waves I and III, for progression of wave I, and at p65 for wave 
IV.  Effects of disease within gender were observed for 8k Hz stimuli (Table XXXI) for 
progression of wave IV, and at p65 for wave II.  For 16k Hz stimuli (Table XXXII), 
effects of disease within gender were observed at p20 for wave III, and at p65 for waves 
II and III.  Effects of disease within gender for 32k Hz stimuli (Table XXXIII) were 
observed at p65 for wave II.  Of the 10 variables at which an effect of disease was 





Table XXX. Results of repeated measures analyses examining effects of disease within gender and test time for ABR amplitude for 
click stimuli.  Comparisons are between female and male mice with (-/-) and without (+/- +/+) disease. 
 (A) p20 Amplitude (B) Amplitude progression/5 days (C) p65 Amplitude 
Click Female Male Female Male Female Male 
 F  
(df, df) 
p value F  
(df, df) 
p value F  
(df, df) 
p value F  
(df, df) 
p value F  
(df, df) 
p value F  
(df, df) 
p value 



































































*   significant at p<.05 level 
** significant at p<.01 level 







Table XXXI. Results of repeated measures analyses examining effects of disease within gender and test time for ABR amplitude for 
an 8k Hz stimulus.  Comparisons are between female and male mice with (-/-) and without (+/- +/+) disease. 
 (A) p20 Amplitude (B) Amplitude progression/5 days (C) p65 Amplitude 
8k Female Male Female Male Female Male 
 F  
(df, df) 
p value F  
(df, df) 
p value F  
(df, df) 
p value F  
(df, df) 
p value F  
(df, df) 
p value F  
(df, df) 
p value 



































































*   significant at p<.05 level 
** significant at p<.01 level 







Table XXXII. Results of repeated measures analyses examining effects of disease within gender and test time for ABR amplitude for 
16k Hz stimulus.  Comparisons are between female and male mice with (-/-) and without (+/- +/+) disease. 
 (A) p20 Amplitude (B) Amplitude progression/5 days (C) p65 Amplitude 
16k Female Male Female Male Female Male 
 F  
(df, df) 
p value F  
(df, df) 
p value F  
(df, df) 
p value F  
(df, df) 
p value F  
(df, df) 
p value F  
(df, df) 
p value 



































































*   significant at p<.05 level 
** significant at p<.01 level 







Table XXXIII. Results of repeated measures analyses examining effects of disease within gender and test time for ABR amplitude for 
32k Hz stimulus.  Comparisons are between female and male mice with (-/-) and without (+/- +/+) disease. 
 (A) p20 Amplitude (B) Amplitude progression/5 days (C) p65 Amplitude 
32k Female Male Female Male Female Male 
 F  
(df, df) 
p value F  
(df, df) 
p value F  
(df, df) 
p value F  
(df, df) 
p value F  
(df, df) 
p value F  
(df, df) 
p value 



































































*   significant at p<.05 level 
** significant at p<.01 level 




Summary and Discussion 
 
Mutant NPC mice were found to have evidence of peripheral and 
retrocochlear auditory dysfunction when compared to findings from control 
animal littermates.  DPOAE findings support a cochlear contribution to the 
hearing loss.  At p20, mutant animals had significantly lower DPOAE levels 
compared to control animals at all but two test frequencies.  Because of 
limitations of the equipment, DPOAEs could only be measured up to 10641 Hz, 
which is lower in frequency than the hearing loss exhibited by ABR measures of 
threshold.  This significant difference in DPOAE level persisted across the 
experimental lifespan such that by p65 mutant mice continued to have lower level 
2f1-f2 distortion products.   
Both groups demonstrated progressive increases in DPOAE level from 
p20 to p65, although the effect was larger and across a broader frequency range 
for control animals.  Such an increase in DPOAE level with age suggests 
continued postnatal maturation occurring in the cochlea through at least p65 in 
this background strain.  Although no developmental data have been published on 
the BALB/c mouse at this early age, a progressive increase in DPOAE level has 
been reported in the C57BL/6J background strain from p9, at which point no 
DPOAEs could be recorded, through p28 where they reach adult-like levels 
(Narui, et al., 2009).  Similar postnatal development in DPOAE level has been 
reported in the rat and gerbil (e.g., Lenoir & Puel, 1987; Norton, Bargones, & 
Rubel, 1991).  In the C57BL/6J strain, development occurred first and was 




investigators did not test at frequencies below 8k Hz.  Similarly, the 
developmental changes observed in both the mutant and control animals in the 
current study were larger in the lower frequencies (< 7k Hz).   
When considering the tonotopic nature of the cochlea, these data indicate 
the basal region may be more developmentally stable in control animals in this 
background strain, and that medial and apical regions are susceptible to 
developmental changes in either the mechanical properties of the basilar 
membrane and/or the electromotility of the outer hair cells during postnatal 
development (Long & Tubis, 1988; Brown, McDowell, & Forge, 1989).  That 
mutant mice did not show as much increase in DPOAE level in low frequencies, 
and no increase in the higher frequencies, provides support that NPC disease 
pathogenesis may disrupt the maturational processes of the developing auditory 
system in mice.  While DPOAE data support a cochlear site of lesion, histology of 
the inner ears of these animals will be necessary to confirm this assertion.  
High frequency hearing loss is present in mutant NPC1 (-/-) mice by 
postnatal day 20 (Figure 31).  Specifically, ABR thresholds are significantly 
elevated at 16k Hz and 32 kHz.  This is weeks before diseased mice become 
otherwise overtly affected by exhibiting neurological symptoms (e.g., ataxia, 
tremor, dystonia).  While it was hypothesized that mutant mice would have high 
frequency hearing loss, given the progressive nature of the disease, it was 
expected that the hearing loss would become evident at a later point in the 
lifespan. The observation of significant hearing loss in all of the mutant animals 




auditory system or developmental dysfunction. Longitudinal data confirm that the 
hearing loss is progressive in mutant mice at all test stimuli (click, 8k, 16k Hz) 
except for 32k Hz, where they have hearing loss present as early as p20.  
 Non-mutant control animals (+/-, +/+) underwent a progressive, age-
related decline in ABR threshold at 32k Hz, but not at lower test frequencies.  The 
BALB/c background strain is known to undergo age-related decline in hearing as 
early as p50.  Willott, et al. (1998) noted an elevation in 24k Hz ABR thresholds 
of BALB/c mice compared to a C57 strain as early as 50 days of age.  The 
investigators speculated that even at this early age BALB/c mice do to not appear 
to hear high frequencies well, although they did not test above 24k Hz.  The 
current data suggest that age-related decline in high frequency hearing (32k Hz) 
can begin much earlier than what was previously reported in BALB/c mice.   
It was hypothesized that mutant animals would exhibit evidence of 
retrocochlear pathology on their ABR findings, much like humans with NPC.  
Furthermore, because the human analysis that sought to uncover progressive 
deterioration in the ABR was inconclusive, perhaps, in part, because of too short 
an experimental window, it was anticipated that these progressive changes could 
be observed in mutant mice. 
The ABR latency analysis and comparison between mutant and control 
animals revealed no significant differences in absolute and interpeak latencies for 
click and 16k Hz stimuli at p20.  For those ABR latencies at 8k and 32k Hz where 
there was a significant difference in latency observed, mutant mice almost always 




early components of the waveform (e.g., waves, I, II, and III) can be explained by 
hearing loss in mutant mice, prolongation in later waves (e.g., wave V) and 
interpeak latencies (e.g., III-V) cannot be explained by peripheral hearing, and 
suggests retrocochlear involvement.  In general, interpeak latency components of 
the ABR are unaffected by pure conductive and cochlear hearing loss, and are 
thought to reflect a delay in brainstem transmission time through the auditory 
brainstem.    
Mutant mice had significantly longer ABR absolute and interpeak 
latencies than control animals by p65.  Given the progressive nature of the 
disease, it was hypothesized that mutant animals would undergo a significant 
prolongation in ABR latencies, perhaps in part because of changes in peripheral 
hearing, but also because of retrocochlear deterioration.  The difference in latency 
between groups at p65 was not a reflection of a prolongation in latencies for the 
mutant group, however, but rather a significant shortening in control-animal 
absolute and interpeak latency.  In general, ABR peak latencies of the mutant 
animals remained stable and, in the few cases where they did change significantly, 
most involved prolongation of absolute latencies of early peaks and a concomitant 
decrease in interpeak latencies.   
Developmental changes in ABR latency in mice have not been reported 
previously in the literature.  While the onset of the ABR (thresholds) has been 
documented in C57BL/6J mice (Narui, et al., 2009), and saturates at 
approximately 14 days, it is not clear what, if any, developmental changes may 




BALB/c background strain, postnatal maturational effects on the ABR do occur, 
and that some aspect of NPC pathogenesis halts this development in affected 
mice.   
Postnatal maturation of the ABR has been well documented in other 
mammals, including humans.  In the human model, ABRs exhibit changes during 
at least the first 18 months of life (e.g., Gorga et al., 1987, 1989), which justifies 
different clinical normative data for this population (for review see Hall, 1992).  
At birth, the ABR waveform is incomplete, typically missing waves II and IV and 
sometimes wave III, and characterized by prolonged interpeak latencies (I-III, III-
V, I-V).   During the first two years of life, as additional component peaks 
emerge, waves III and V become progressively shorter in latency.  Evidence 
suggests that in humans, the peripheral auditory system matures faster than the 
central nervous system (e.g., Montandon, Cao, Engel, & Grajew, 1979), which 
explains why wave I is more prominent in newborns than adults.  Prolongations in 
interpeak latency are purported to reflect an immature central nervous system, 
specifically incomplete nerve myelinization, reduced axon diameter, and 
immature synaptic function (e.g., Schwartz, et al., 1989) all of which are believed 
to develop postnatally. 
It would appear that a similar maturation is taking place in the auditory 
system of the BALB/c mouse where almost every component peak of the ABR 
exhibited significant progressive shortening across the experimental lifespan.   
That the maturation effect was larger for later-occurring waves is supported by the 




auditory nervous system.  In general, however, this effect was absent in mutant 
animals, lending further support to a disruption in the development of the auditory 
system in diseased mice.  ABR abnormalities reported here are consistent with the 
histological auditory brainstem pathology identified in 8-week-old NPC mutant 
mice by Luan et al. (2008).  Specifically, the investigators documented lower 
neural density in the cochlear nucleus and a proliferation of astrocytes in the 
inferior colliculus and medial geniculate nucleus of diseased animals.  In order to 
definitively link the abnormal histology reported by these investigators with the 
auditory dysfunction shown in the current data, future studies examining 
histology and auditory function in the same animals are necessary.   
ABR amplitude findings showed no evidence of a clear effect of disease in 
the lower test frequencies, but did reveal smaller amplitudes in mutant mice, 
primarily in the early ABR peaks, at 16k and 32k Hz, which is consistent with the 
documented high frequency hearing loss.  Amplitude of the ABR depends on both 
the number of neurons activated by an incoming stimulus, and their 
synchronization when firing.  Cochlear hearing loss, especially in the high 
frequencies, is known to affect both aspects of neural activation and is often 
reflected by decreased amplitude in the early components of the ABR in humans 
(e.g., Picton, Woods, Baribeau-Braun, & Healey, 1977).  The ABR amplitude 
data presented here also reflects evidence of maturational change in the 
waveform.  Both murine groups demonstrated significant decline in waveform 




Effects of gender on DPOAE and ABR findings were not significant in 
most analyses, although the few effects that were identified in DPOAE level and 
ABR latency progression implicated a greater effect of disease on male mice than 
female mice.  Gender differences are not considered part of the phenotype for 
NPC, however Võikar, et al. (2002) observed that in several measures of 
cognitive function and motor impairment, male NPC (-/-) mice were more 
affected than females.  Similar gender differences have been reported elsewhere 
in other neurodegenerative mouse models with cerebellar involvement in which 
female mutant mice were less affected neurologically and showed less 
deterioration in their neuroanatomy than their male counterparts (Doulazmi, et al, 
1999; Henderson, et al., 2000; Ogura, Matsumoto, Mikoshiba, 2001).  
Anecdotally, the female mutant mice in the current study showed more 
exploratory activity and less weight loss near the end of the experimental lifespan 
than male mice, but the minimal effects observed on hearing are not sufficiently 












CHAPTER 4: COMPREHENSIVE DISCUSSION AND SUMMARY 
The two experiments described in this document used a comparative, 
translational approach to evaluate comprehensively the auditory phenotype 
associated with NPC.  Although limited literature suggested that hearing loss may 
be related to the disease, the degree, progression, and site of lesion associated 
with the possible hearing loss in NPC have not been reported.  In the current 
study, overall findings confirm widespread auditory dysfunction is part of the 
disease process of NPC in both humans and the (BALB/cNctr-Npc1m1N/J) mouse 
model.  This has valuable implications for researchers seeking to understand 
better the natural history of the disease, and clinicians and families who aim to 
provide the best quality of care for their patients and loved ones.   
Results of experiment one confirm a pervasive high frequency hearing loss 
that is sensorineural in nature in a large proportion of patients with NPC.  It is not 
possible to determine the precise onset of hearing loss in the human population, 
although data from the current study suggest it may vary.  Nonetheless, this was a 
predominately pediatric population in whom high frequency hearing loss was 
common.  High frequency hearing loss in children, in the absence of noise 
exposure, can result from several non-hereditary etiologies, including, but not 
limited to: ototoxicity, toxoplasmosis, congenital syphilis, Rh-incompatibility, 
cytomegalovirus, and other herpes simplex viruses.  While hearing loss in a child 
is unexpected, it is unlikely that early onset high frequency hearing loss alone can 
serve as an early indication of NPC.  The combination of hearing loss and hepatic 




mucopolysaccharidosis) and more awareness on the auditory manifestations 
associated with NPC may result in its inclusion in this list.  However, this 
association is further confounded by evidence that not all patients with NPC in 
this study exhibited hearing loss.  
While the heterogeneity and small size of the sample made it difficult to 
identify variables, such as gender and age at disease onset, that may contribute to 
hearing loss in NPC, results among patients were consistent sufficiently to point 
to a mixed (cochlear and retrocochlear) site of lesion in most individuals, with 
some patients exhibiting a profile for auditory neuropathy spectrum disorder 
(ANSD).  However, not all patients exhibited the same degree of impairment or 
site of lesion suggesting a possible confounding influence of genetic and 
environmental modifiers.  There are over 240 disease-causing mutations 
associated with NPC (Runz, 2009).  This fact alone limits significantly the ability 
to determine phenotype-genotype correlations in a human population with NPC; 
however, it is probable that such molecular heterogeneity contributes to the large 
variability in auditory function observed in the current study.    
Cross-sectional data, in combination with several case examples from 
individuals who provided longitudinal behavioral data, support a progressive 
decline in hearing in at least some individuals.  These data represent the first 
conclusive report of progressive auditory dysfunction in patients with NPC and 
suggest the auditory system is vulnerable to disease-related pathological insult 




Five late-onset cases of the disease were evaluated separately because of 
their unique audiological profiles.  All of these patients presented with hearing 
loss, and in at least three cases, hearing loss was a premonitory symptom of the 
disease.  Although the sample size is small, in conjunction with other reports of 
hearing loss as an early manifestation of this variant (Sévin, et al., 2007), this 
finding seems sufficiently robust to conclude that NPC should be considered in 
the differential diagnosis of all patients with subtle neurological involvement 
(e.g., learning delay) and idiopathic hearing loss. 
Auditory dysfunction has been reported in several other lysosomal storage 
diseases that affect children, including Gaucher disease type 3 (Bamiou, et al., 
2001), Fabry disease (Palla, et al., 2007; Ries, et al., 2007), 
mucopolysaccharidoses (e.g., Schachern, et al., 2007) and Pompe disease 
(Capelle, et al., 2010); however none of these disorders affects the auditory 
system in ways similar to NPC.  With the exception of limited evidence for a 
mixed site of lesion in Pompe disease, the phenotypes associated with these 
disorders do not include robust evidence for cochlear and retrocochlear 
involvement such as that which has been described in the current study on NPC.  
The auditory system may have a useful role in distinguishing NPC from other 
lysosomal storage diseases early in the diagnostic process before cytological and 
biochemical assessment can occur.  
 Results of experiment two identify for the first time auditory dysfunction 
in the mouse model for NPC disease.  High frequency hearing loss is present at 




(click, 8k, 16k, 32k Hz) across the experimental lifespan to p65.  DPOAE data 
support a cochlear contribution to the hearing loss, although future histology will 
be necessary to confirm this hypothesis.  Maturational change in control animals 
was observed for both DPOAE 2f1-f2 level and for ABR latencies, which 
progressively increased and shortened, respectively.  These DPOAE and ABR 
changes typically did not take place in mutant mice, or occurred to a significantly 
smaller degree, suggesting a halt in the developmental processes of the auditory 
system in diseased animals.  
 The principal biochemical defect in NPC is an over-accumulation of 
exogenous and unesterified cholesterol throughout the body, most notably in the 
central nervous system and visceral organs.  The relationship between over-
accumulation of cholesterol and hearing has been examined, but remains unclear.  
In humans, inconclusive evidence has been offered to suggest a correlation 
between elevated blood cholesterol and triglyceride levels (hyperlipidemia) with 
sensorineural hearing loss (e.g., Evans, et al., 2006).  Detrimental effects from 
hyperlipidemia on DPOAE amplitude (Preyer, Baisch, Bless, & Gummer, 2001) 
and pure-tone thresholds have also been reported, with speculation that the effect 
may be greater at the basal and high frequency test region where the cochlea is 
more susceptible to ischemic change (Cunningham & Goetzinger, 1974).  Similar 
harmful outcomes of hyperlipidemia on hearing and cochlear morphology have 
been shown in mice (Guo, Zhang, Du, Nair, & Yoo, 2005) and guinea pigs, 
although short-term dietary changes (influx or reduction in high-fat diet) have not 




intake and the use of pharmacologic statins to reduce the production of cholesterol 
have not been effective in treating NPC.  It is unlikely the underlying cause of 
hearing loss associated with hyperlipidemia and NPC is the same, but it does 
implicate a role for cholesterol and other lipids in the auditory system, and 
suggests their function may be widespread and complex. 
 Cholesterol is a critical component in regulating mammalian plasma 
membrane properties such as lateral mobility, permeability, and stiffness (Organ 
& Raphael, 2009) among other important functions.  Within the cochlea, 
cholesterol regulates lipid composition, mobility, and stiffness of the lateral walls 
of the outer hair cells (Evans, et al., 2006). Rajagopalan, et al. (2007) showed that 
changes in cochlear cholesterol levels modulated the amplitude of DPOAEs in 
mice.  By altering cholesterol in the outer hair cell wall, the investigators were 
able to show a relationship between membrane cholesterol levels and the 
membrane protein prestin, which regulates motility of the sensory cells, thereby 
indirectly affecting outer hair cell tuning.  When cholesterol was depleted in the 
outer hair cells, hearing loss was evident by a reduction in DPOAE level.  Adding 
cholesterol back to the cells initially improved hearing, but was followed by a 
decrease in hair cell electromotility and DPOAE level.  The investigators showed 
also a decrease in the amount of membrane cholesterol during maturation of the 
OHCs, and they concluded this normal reduction during the process of maturation 
helps to tune the sensory cells to function maximally.  Levic and Yamoah (2011) 
observed a similar maturational effect from cholesterol within cochlear outer hair 




magnitude of voltage-gated potassium currents within outer hair cells, and this 
effect was only important in developing but not mature cells. 
These recent reports highlighting the critical role of cholesterol in 
developing hair cells may explain why DPOAEs from mutant NPC mice in the 
current study did not achieve levels consistent with their control littermates during 
the maturation process.  It is possible disease-related alterations in the processing 
of cellular cholesterol prohibit the normal reduction in cholesterol necessary for 
cells to completely mature.  As unesterified cholesterol, sphingolipids, and 
gangliosides accrue within cells throughout the disease process, further 
detrimental effects on cellular structure and function are likely, and may manifest 
as progressive declines in auditory function.  This hypothesis applies to both 
cochlear cells, and lipid-dense areas of neural tissue, including the myelinated 
auditory nerve, that may account for both the cochlear and retrocochlear 
dysfunction observed in all NPC mice and most humans in the current study. 
The auditory phenotype observed in humans with NPC and mutant mice is 
relatively consistent, although not completely parallel.  All mutant mice exhibited 
early-onset high-frequency hearing loss, cochlear and retrocochlear dysfunction, 
evidence of a disruption in cochlear and auditory brainstem maturation, and 
progression of hearing loss.  High frequency hearing loss was common in humans 
with NPC, as was a mixed (cochlear and retrocochlear) site of lesion.  Progressive 
hearing loss also was evident in some individuals; however, not all patients with 
NPC exhibited auditory dysfunction.  This variability between a heterogeneous, 




inbred species is not surprising.  That auditory dysfunction was consistently 
observed in all NPC mice and a majority of patients with NPC leaves little doubt, 
however, that NPC pathology can detrimentally affect the auditory system.   
High frequency hearing loss is an early-onset manifestation of the disease 
in NPC mice that occurs weeks prior to other observable neurological symptoms 
(e.g., ataxia).  It is unclear when hearing loss in humans with NPC firsts 
manifests.  This is a difficult question to answer, in part because of the variability 
in the auditory phenotype observed, and also because many patients (23 in the 
current study) were unaware of their hearing loss, suggesting the hearing loss was 
present for some time and simply undetected.  It seems likely that the auditory 
system can serve as a useful clinical marker for disease onset and progression in 
the mouse model of NPC where a robust phenotype was observed.  The 
combination of auditory data, such as those reported in the current study, and 
auditory histology will have important implications for understanding better the 
pathophysiology of the disease and the role of NPC1 in the auditory system.  The 
early onset of the auditory phenotype and evidence for disruption of auditory 
maturation provides new insights into understanding disease behavior and 
progression, and offers a useful tool for evaluating the efficacy of future 
therapeutic interventions.  The BALB/cNctr-Npc1m1N/J strain of mice has been 
described as a model for severe human NPC disease, and alternate murine models 
are under development (Madra & Sturley, 2010).  The current study supports 




 Data presented here represent the largest cohort of patients with NPC 
evaluated comprehensively for auditory dysfunction, and for the first time explore 
auditory manifestations in the (BALB/cNctr-Npc1m1N/J) mouse model.  Taken 
together, these data implicate the pathological processes of NPC in the 
manifestation of hearing loss and auditory dysfunction.  It is important that 
clinicians and researchers be aware of the involvement of the auditory system, 
which has historically has been an overlooked component of the disorder, as 
hearing loss in some patients will affect daily communication.  Patients with NPC 
should be routinely monitored for hearing loss throughout their lives from the 
time of diagnosis.  Clinicians should be aware of the obstacles that may exist in 
obtaining comprehensive behavioral evaluations in some patients with NPC and 
the value of electrophysiological or other objective measures of auditory system 
integrity in the evaluation of hearing.  Emphasis should be placed on the 
collection of high-frequency information, as even minimal hearing loss in this 
region can have deleterious effects on social and academic progress.  Families 
should be counseled regarding the implications for communication involved with 
cochlear hearing loss and disorders of the auditory nerve, most notably difficulty 
listening in background noise and in the absence of visual cues.  
 While the data presented here are comprehensive, there are several 
questions that remain.  In the human population with NPC, will ABR data 
ultimately show progressive deterioration and, if so, what is the time course of 
such change?  It is unlikely, given the heterogeneity of the sample and the large 




that the auditory system will serve independently as a clinical marker, for 
example, in future therapeutic trials.  However, enough data have been presented 
here to suggest that the absence of hearing loss or the lack of progression in some 
patients may well indicate a potential therapeutic benefit from intervention in 
some patients with NPC.  It seems more likely, however, that auditory function in 
the mouse model will serve sooner as a guide for intervention efficacy.  To 
elucidate further the pathogenesis of the findings presented here and perhaps 
understand better the effect of potential treatments, histology of the cochlear and 
auditory brainstem pathways will be a necessary component of future work with 
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Glossary:  All definitions were obtained from Stedman’s Medical Dictionary, 27th 
Edition, Baltimore. 
 
Ascites: Abnormal accumulation of fluid in the abdomen 
 
Anamnestic: 1. Assisting the memory 2. Relating to the medical history of a 
patient 
 
Astrocyte: One of the large neuroglia cells of the nervous tissue.  SEE ALSO 
neuroglia 
 
Ataxia: An inability to coordinate muscle activity during voluntary movement; 
most often due to disorders of the cerebellum or the posterior columns of the 
spinal cord; may involve the limbs, head, or trunk 
 
Cataplexy: A transient attack of extreme generalized weakness, often precipitated 
by an emotional response, such as surprise, fear, or anger; one component of the 
narcolepsy quadrad   
 
Cholestasis: An arrest in the flow of bile; c. due to obstruction of bile ducts is 
accompanied by formation of plugs of inspissated bile in the small ducts, 
canaliculi in the liver, and elevation of serum direct bilirubin and some enzymes. 
 
Complementation: Interaction between two genetic units, one or both of which are 
defective, permitting the organism containing these units to function normally, 
whereas it could not do so if either unit were absent. 
 
Cytological: Relating to cytology 
 
Cytology: They study of the anatomy, physiology, pathology, and chemistry of 
the cell. SYN Cellular biology, cytobiology  
 
Dysarthria: A disturbance of speech due to emotional stress, to brain injury, or to 
paralysis, incoordination, or spasticity of the muscles used for speaking  
 
Dysphagia: Difficulty in swallowing 
 
Dystonia: A state of abnormal (either hypo- or hyper-) tonicity in any of the 
tissues resulting in impairment of voluntary movement 
 
Esterification: The process of forming an ester, as in the reaction of ethanol and 





Ganglioside: A glycosphingolipid chemically similar to cerebrosides but 
containing one or more sialic acid residues; found principally in nerve tissue, 
spleen, and thymus  
 
Hepatosplenomegaly: Enlargement of the liver and spleen 
 
Hypotonia: A condition in which there is diminution or loss of muscular tonicity 
 
Lipid: “Fat-soluble” an operational term describing a solubility characteristic, not 
a chemical substance, i.e., denoting substances extracted from animal or vegetable 
cells by nonpolar solvents; included in the heterogeneous collection of materials 
thus extractable are fatty acids, glycerides and glyceryl ethers, phospholipids, 
sphingolipids, long-chain alcohols and waxes, terpenes, steroids, and “fat-soluble” 
vitamins such as A, D, and E    
 
Lysosome: A cytoplasmic membrane-bound vesicle measuring 5-8 nm and 
containing a wide variety of glycoprotein hydrolytic enzymes active at an acid 
pH; serves to digest exogenous material, such as bacteria, as well as effete 
organelles of the cells 
 
Neuroglia: Non-neuronal cellular elements of the central and peripheral nervous 
system; formerly believed to be merely supporting cells but now thought to have 
important metabolic functions, since they are invariably interposed between 
neurons and the blood vessels supplying the nervous system.  In central nervous 
tissue they include oligodendroglia cells, astrocytes, ependymal cells, and 
microglia cells.  The satellite cells of ganglia and the neurolemmal or Schwann 
cells around peripheral nerve fibers can be interpreted as the oligodendroglia cells 
of the peripheral nervous system 
 
Pleiotropy: Production by a single mutant gene of apparently unrelated multiple 
effects at the clinical or phenotypic level 
 
Sphingolipid: Any lipid containing a long-chain base like that of sphingosine; a 
constituent of nerve tissue 
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